Cancer Research and Treatment

Original Articles

Evaluating the Effects of Mindfulness-Based Self-Help via an OTT Platform on Breast Cancer Patients Undergoing Radiotherapy: A Prospective Non-Randomized Controlled Trial: Hyejo Ryu, Si Nae You, Sohee Oh, Bora Kim, Jeong-Hyun Kim, In Ah Kim; Received October 1, 2024 Accepted November 20, 2024 Published online November 25, 2024; DOI: https://doi.org/10.4143/crt.2024.955 [Accepted]

Abstract PDF: Purpose
Previous research showed the benefits of mindfulness meditation on the mental health and quality of life of breast cancer patients. Traditionally, these programs relied on in-person interactions, but the COVID-19 pandemic necessitated alternative delivery methods. This study evaluated the effectiveness and feasibility of a mindfulness-based self-help (MBSH) program via Netflix for breast cancer patients undergoing radiotherapy.
Materials and Methods
This prospective non-randomized controlled study assigned patients to a control or MBSH group based on age and preference. The MBSH group watched episodes of "Headspace Guide to Meditation" on Netflix and practiced guided meditation at least twice per week for four weeks. Participants completed questionnaires assessing depression, anxiety, stress, insomnia, mindfulness, mental adjustment to cancer, and quality of life at weeks 0 and 8. Data were analyzed using a two-way repeated measures ANOVA.
Results
Ninety-six patients participated, with 84 eligible for final analysis (44 control, 40 MBSH). Intention-to-treat analysis revealed a significant improvement in depression (f=4.306, p=0.041). Half of the experimental group (n = 20) adhered to the study protocol. At week 8, the experimental group showed significant improvement compared to the control group in cognitive avoidance (f=8.530, p=0.005) and positive attitude (f=5.585, p=0.021), both indicative of adaptive coping strategies.
Conclusion
This study firstly investigated the effect and feasibility of a Netflix-based MBSH program for breast cancer patients undergoing radiotherapy. Findings suggest MBSH on Netflix can improve mental health and adaptive mental adjustment, highlighting the potential of self-help mindfulness interventions to enhance the well-being of cancer patients and need for further research.

415 View
25 Download

To Use or Not to Use: Temozolomide in Elderly Patients with IDH Wild-type MGMT Promoter Unmethylated Glioblastoma Treated with Radiotherapy: Chan Woo Wee, Joo Ho Lee, Hye In Lee, Jina Kim, Jong Hee Chang, Seok-Gu Kang, Eui Hyun Kim, Ju Hyung Moon, Jaeho Cho, Chul-Kee Park, Chae-Yong Kim, Kihwan Hwang, Hong In Yoon, In Ah Kim; Received September 27, 2024 Accepted November 9, 2024 Published online November 11, 2024; DOI: https://doi.org/10.4143/crt.2024.945 [Accepted]

Abstract PDF: Purpose
To identify a specific subgroup of patients among elderly glioblastoma patients aged 70 years or older with unmethylated MGMT promoters (eGBM-unmethylated) who would significantly benefit from the addition of temozolomide (TMZ) to radiotherapy (RT).
Materials and Methods
Newly diagnosed patients with IDH wild-type eGBM-unmethylated treated with RT were included in this multicenter analysis (n=182). RT dose was 45 Gy in 15 fractions (62.3%), 60 Gy in 30 fractions, or 61.2 Gy in 34 fractions. For patients treated with RT plus TMZ (60.4%), TMZ was administered concurrently with RT, followed by six adjuvant cycles. The primary endpoint was overall survival.
Results
During a median follow-up of 11.3 months for survivors, the median survival was 12.2 months. The median survival duration significantly improved with the addition of TMZ to RT compared with that with RT alone (13.6 months vs. 10.5 months, p=0.028). In the multivariable analysis adjusted for clinical, radiological, and genetic biomarkers, the addition of TMZ significantly improved overall survival (hazard ratio, 0.459; p=0.006). In subgroup analysis, median survival was especially improved by 4–5 months in patients with residual disease (p<0.001), Karnofsky Performance Status ≥60 (p=0.033), and age ≤75 years (p=0.090). A significant benefit of TMZ was noted only in patients with two or three of the above factors (median survival, 14.1 months vs. 10.5 months, p=0.014).
Conclusion
The addition of TMZ significantly improved the survival of patients with eGBM-unmethylated treated with RT. The suggested criteria for the specific subgroup in these patients warrant external validation for clinical application.

465 View
41 Download

Choosing Wisely between Radiotherapy Dose-Fractionation Schedules: The Molecular Graded Prognostic Assessment for Elderly Glioblastoma Patients: Hye In Lee, Jina Kim, In Ah Kim, Joo Ho Lee, Jaeho Cho, Rifaquat Rahman, Geoffrey Fell, Chan Woo Wee, Hong In Yoon; Received July 22, 2024 Accepted September 10, 2024 Published online September 11, 2024; DOI: https://doi.org/10.4143/crt.2024.680 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to develop a graded prognostic assessment (GPA) model integrating genomic characteristics for elderly patients with glioblastoma (eGBM), and to compare the efficacy of different radiotherapy schedules.
Materials and Methods
This multi-institutional retrospective study included patients aged ≥ 65 years who underwent surgical resection followed by radiotherapy with or without temozolomide (TMZ) for newly diagnosed eGBM. Based on the significant factors identified in the multivariate analysis for overall survival (OS), the molecular GPA for eGBM (eGBM-molGPA) was established.
Results
A total of 334 and 239 patients who underwent conventionally fractionated radiotherapy (CFRT) and hypofractionated radiotherapy (HFRT) were included, respectively, with 86% of patients receiving TMZ-based chemoradiation. With a median follow-up of 17.4 months (range, 3.3 to 149.9 months), the median OS was 18.7 months for CFRT+TMZ group, 15.1 months for HFRT+TMZ group, and 10.4 months for radiotherapy alone group (CFRT+TMZ vs. HFRT+TMZ: hazard ratio [HR], 1.52; p < 0.001 and CFRT+TMZ vs. radiotherapy alone: HR, 2.52; p < 0.001). In a combined analysis with the NOA-08 and Nordic trials, CFRT+TMZ group exhibited the highest survival rates among all treatment groups. The eGBM-molGPA, which integrated four clinical and three molecular parameters, stratified patients into low-, intermediate-, and high-risk groups. CFRT+TMZ significantly improved OS compared to HFRT+TMZ or radiotherapy alone in the low-risk (p=0.023) and intermediate-risk groups (p < 0.001). However, in the high-risk group, there was no significant difference in OS between treatment options (p=0.770).
Conclusion
CFRT+TMZ may be more effective than HFRT+TMZ or radiotherapy alone for selected eGBM patients. The novel eGBM-molGPA model can guide treatment selection for this patient population.

518 View
61 Download

Breast cancer

Locoregional Recurrence in Adenoid Cystic Carcinoma of the Breast: A Retrospective, Multicenter Study (KROG 22-14): Sang Min Lee, Bum-Sup Jang, Won Park, Yong Bae Kim, Jin Ho Song, Jin Hee Kim, Tae Hyun Kim, In Ah Kim, Jong Hoon Lee, Sung-Ja Ahn, Kyubo Kim, Ah Ram Chang, Jeanny Kwon, Hae Jin Park, Kyung Hwan Shin; Cancer Res Treat. 2025;57(1):150-158. Published online July 12, 2024; DOI: https://doi.org/10.4143/crt.2024.201

Abstract PDF PubReader ePub: Purpose
This study aims to evaluate the treatment approaches and locoregional patterns for adenoid cystic carcinoma (ACC) in the breast, which is an uncommon malignant tumor with limited clinical data.
Materials and Methods
A total of 93 patients diagnosed with primary ACC in the breast between 1992 and 2022 were collected from multi-institutions. All patients underwent surgical resection, including breast-conserving surgery (BCS) or total mastectomy (TM). Recurrence patterns and locoregional recurrence-free survival (LRFS) were assessed.
Results
Seventy-five patients (80.7%) underwent BCS, and 71 of them (94.7%) received post-operative radiation therapy (PORT). Eighteen patients (19.3%) underwent TM, with five of them (27.8%) also receiving PORT. With a median follow-up of 50 months, the LRFS rate was 84.2% at 5 years. Local recurrence (LR) was observed in five patients (5.4%) and four cases (80%) of the LR occurred in the tumor bed. Three of LR (3/75, 4.0%) had a history of BCS and PORT, meanwhile, two of LR (2/18, 11.1%) had a history of mastectomy. Regional recurrence occurred in two patients (2.2%), and both cases had a history of PORT with (n=1) and without (n=1) irradiation of the regional lymph nodes. Partial breast irradiation (p=0.35), BCS (p=0.96) and PORT in BCS group (p=0.33) had no significant association with LRFS.
Conclusion
BCS followed by PORT was the predominant treatment approach for ACC of the breast and LR mostly occurred in the tumor bed. The findings of this study suggest that partial breast irradiation might be considered for PORT in primary breast ACC.

1,004 View
108 Download

Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy: Dowook Kim, Jin Ho Kim, In Ah Kim, Ji Hyun Chang, Kyung Hwan Shin; Cancer Res Treat. 2023;55(2):592-602. Published online October 11, 2022; DOI: https://doi.org/10.4143/crt.2022.998

Abstract PDF Supplementary Material PubReader ePub

Purpose
The utility of postmastectomy radiation therapy (PMRT) for breast cancer patients after neoadjuvant chemotherapy (NAC) is highly controversial. This study evaluated the impact of PMRT according to pathologic nodal status after modern NAC.
Materials and Methods
We retrospectively reviewed 682 patients with clinical stage II-III breast cancer who underwent NAC and mastectomy from 2013 to 2017. In total, 596 patients (87.4%) received PMRT, and 86 (12.6%) did not. We investigated the relationships among locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), overall survival (OS), and various prognostic factors. Subgroup analyses were also performed to identify patients who may benefit from PMRT.
Results
The median follow-up duration was 67 months. In ypN+ patients (n=368, 51.2%), PMRT showed significant benefits in terms of LRRFS, DFS, and OS (all p < 0.001). In multivariate analyses, histologic grade (HG) III (p=0.002), lymphovascular invasion (LVI) (p=0.045), and ypN2-3 (p=0.02) were significant risk factors for poor LRRFS. In ypN1 patients with more than two prognostic factors among luminal/human epidermal growth factor receptor-2–negative subtype, HG I-II, and absence of LVI, PMRT had no significant effect on LRRFS (p=0.18). In ypN0 patients (n=351, 48.8%), PMRT was not significantly associated with LRRFS, DFS, or OS. However, PMRT showed better LRRFS in triple-negative breast cancer (TNBC) patients (p=0.03).
Conclusion
PMRT had a major impact on treatment outcomes in patients with residual lymph nodes following NAC and mastectomy. Among ypN0 patients, PMRT may be beneficial only for those with TNBC.

Citations

Citations to this article as recorded by

Analysis of Individualized Silicone Rubber Bolus Using Fan Beam Computed Tomography in Postmastectomy Radiotherapy: A Dosimetric Evaluation and Skin Acute Radiation Dermatitis Survey
Xue-mei Chen, Chen-di Xu, Li-ping Zeng, Xiao-tong Huang, Ao-qiang Chen, Lu Liu, Liu-wen Lin, Le-cheng Jia, Hua Li, Xiao-bo Jiang
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
Munaser Alamoodi
European Journal of Breast Health.2024; 20(2): 81. CrossRef
Oncological outcomes of stage I–II breast cancer treatment after subcutaneous/skin-sparing mastectomies with reconstruction
E. A. Rasskazova, A. D. Zikiryakhodzhaev
MD-Onco.2024; 4(3): 37. CrossRef
Effectiveness of mat pilates on fatigue in women with breast cancer submitted to adjuvant radiotherapy: randomized controlled clinical trial
Daniele Medeiros Torres, Kelly de Menezes Fireman, Erica Alves Nogueira Fabro, Luiz Claudio Santos Thuler, Rosalina Jorge Koifman, Anke Bergmann, Sabrina da Silva Santos
Supportive Care in Cancer.2023;[Epub] CrossRef
The Role of Sentinel Lymph Node Biopsy in Breast Cancer Patients Who Become Clinically Node-Negative Following Neo-Adjuvant Chemotherapy: A Literature Review
Giulia Ferrarazzo, Alberto Nieri, Emma Firpo, Andrea Rattaro, Alessandro Mignone, Flavio Guasone, Augusto Manzara, Giuseppe Perniciaro, Stefano Spinaci
Current Oncology.2023; 30(10): 8703. CrossRef

5,738 View
215 Download
5 Web of Science
5 Crossref

CNS cancer

Suggestions for Escaping the Dark Ages for Pediatric Diffuse Intrinsic Pontine Glioma Treated with Radiotherapy: Analysis of Prognostic Factors from the National Multicenter Study: Hyun Ju Kim, Joo Ho Lee, Youngkyong Kim, Do Hoon Lim, Shin-Hyung Park, Seung Do Ahn, In Ah Kim, Jung Ho Im, Jae Wook Chung, Joo-Young Kim, Il Han Kim, Hong In Yoon, Chang-Ok Suh; Cancer Res Treat. 2023;55(1):41-49. Published online March 4, 2022; DOI: https://doi.org/10.4143/crt.2021.1514

Abstract PDF Supplementary Material PubReader ePub

Purpose
This multicenter retrospective study aimed to investigate clinical, radiologic, and treatment-related factors affecting survival in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) treated with radiotherapy.
Materials and Methods
Patients aged <30 years who underwent radiotherapy as an initial treatment for DIPG between 2000 and 2018 were included; patients who did not undergo magnetic resonance imaging at diagnosis and those with pathologically diagnosed grade I glioma were excluded. We examined medical records of 162 patients collected from 10 participating centers in Korea. The patients’ clinical, radiological, molecular, and histopathologic characteristics, and treatment responses were evaluated to identify the prognosticators for DIPG and estimate survival outcomes.
Results
The median follow-up period was 10.8 months (interquartile range, 7.5 to 18.1). The 1- and 2-year overall survival (OS) rates were 53.5% and 19.0%, respectively, with a median OS of 13.1 months. Long-term survival rate (≥ 2 years) was 16.7%, and median OS was 43.6 months. Age (< 10 years), poor performance status, treatment before 2010, and post-radiotherapy necrosis were independently associated with poor OS in multivariate analysis. In patients with increased post-radiotherapy necrosis, the median OS estimates were 13.3 months and 11.4 months with and without bevacizumab, respectively (p=0.138).
Conclusion
Therapeutic strategy for DIPG has remained unchanged over time, and the associated prognosis remains poor. Our findings suggest that appropriate efforts are needed to reduce the occurrence of post-radiotherapy necrosis. Further well-designed clinical trials are recommended to improve the poor prognosis observed in DIPG patients.

Citations

Citations to this article as recorded by

Advancements in Image-Based Models for High-Grade Gliomas Might Be Accelerated
Guido Frosina
Cancers.2024; 16(8): 1566. CrossRef
The relationship between imaging features, therapeutic response, and overall survival in pediatric diffuse intrinsic pontine glioma
Xiaojun Yu, Mingyao Lai, Juan Li, Lichao Wang, Kunlin Ye, Dong Zhang, Qingjun Hu, Shaoqun Li, Xinpeng Hu, Qiong Wang, Mengjie Ma, Zeyu Xiao, Jiangfen Zhou, Changzheng Shi, Liangping Luo, Linbo Cai
Neurosurgical Review.2024;[Epub] CrossRef
Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma
Lauren M. Arms, Ryan J. Duchatel, Evangeline R. Jackson, Pedro Garcia Sobrinho, Matthew D. Dun, Susan Hua
Journal of Controlled Release.2024; 370: 835. CrossRef
Pediatric diffuse intrinsic pontine glioma radiotherapy response prediction: MRI morphology and T2 intensity-based quantitative analyses
Xiaojun Yu, Shaoqun Li, Wenfeng Mai, Xiaoyu Hua, Mengnan Sun, Mingyao Lai, Dong Zhang, Zeyu Xiao, Lichao Wang, Changzheng Shi, Liangping Luo, Linbo Cai
European Radiology.2024; 34(12): 7962. CrossRef

5,490 View
221 Download
7 Web of Science
4 Crossref

Breast cancer

The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12): Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim; Cancer Res Treat. 2022;54(4):1121-1129. Published online December 31, 2021; DOI: https://doi.org/10.4143/crt.2021.1083

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods
We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results
Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion
The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.

Citations

Citations to this article as recorded by

Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C
Breast Cancer Research and Treatment.2023; 200(1): 37. CrossRef

6,449 View
184 Download
1 Web of Science
1 Crossref

CNS cancer

The Role of Postoperative Radiotherapy in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma: A Multi-institutional Retrospective Study (KROG 18-11): Joo Ho Lee, Seung Hyuck Jeon, Chul-Kee Park, Sung-Hye Park, Hong In Yoon, Jong Hee Chang, Chang-Ok Suh, Su Jeong Kang, Do Hoon Lim, In Ah Kim, Jin Hee Kim, Jung Ho Im, Sung-Hwan Kim, Chan Woo Wee, Il Han Kim; Cancer Res Treat. 2022;54(1):65-74. Published online March 24, 2021; DOI: https://doi.org/10.4143/crt.2021.142

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the role of postoperative radiotherapy (PORT) in intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC).
Materials and Methods
A total of 133 patients with histologically confirmed HPC were included from eight institutions. Gross total resection (GTR) and subtotal resection (STR) were performed in 86 and 47 patients, respectively. PORT was performed in 85 patients (64%). The prognostic effects of sex, age, performance, World Health Organization (WHO) grade, location, size, Ki-67, surgical extent, and PORT on local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) were estimated by univariate and multivariate analyses.
Results
The 10-year PFS, and OS rates were 45%, and 71%, respectively. The multivariate analysis suggested that PORT significantly improved LC (p < 0.001) and PFS (p < 0.001). The PFS benefit of PORT was maintained in the subgroup of GTR (p=0.001), WHO grade II (p=0.001), or STR (p < 0.001). In the favorable subgroup of GTR and WHO grade II, PORT was also significantly related to better PFS (p=0.028). WHO grade III was significantly associated with poor DMFS (p=0.029). In the PORT subgroup, the 0-0.5 cm margin of the target volume showed an inferior LC to a large margin with 1.0-2.0 cm (p=0.021). Time-dependent Cox proportion analysis showed that distant failures were significantly associated with poor OS (p=0.003).
Conclusion
This multicenter study supports the role of PORT in disease control of intracranial SFT/HPC, irrespective of the surgical extent and grade. For LC, PORT should enclose the tumor bed with sufficient margin.

Citations

Citations to this article as recorded by

Does Adjuvant Radiotherapy Enhance Survival in Intracranial Solitary Fibrous Tumor Patients?
Sakhr Alshwayyat, Haya Kamal, Tala Abdulsalam Alshwayyat, Mustafa Alshwayyat, Mesk Alkhatib, Ayah Erjan
World Neurosurgery.2025; 194: 123545. CrossRef
Application and effect evaluation of microsurgical resection combined with intensity-modulated radiation therapy in the treatment of intracranial solitary fibrous tumor/hemangiopericytoma
Jingcheng Jiang, Xiaoqin Qu, Han Wang, Chao Zhang, Qingshan Deng, Xiaoping Xu, Jun Qiu, Lihua Qu, Yong Yi
Medicine.2025; 104(6): e41336. CrossRef
Development of an MRI‐Based Comprehensive Model Fusing Clinical, Radiomics and Deep Learning Models for Preoperative Histological Stratification in Intracranial Solitary Fibrous Tumor
Xiaohong Liang, Kaiqiang Tang, Xiaoai Ke, Jian Jiang, Shenglin Li, Caiqiang Xue, Juan Deng, Xianwang Liu, Cheng Yan, Mingzi Gao, Junlin Zhou, Liqin Zhao
Journal of Magnetic Resonance Imaging.2024; 60(2): 523. CrossRef
Meningeal Solitary Fibrous Tumor: A Single-Center Retrospective Cohort Study
Siyer Roohani, Yasemin Alberti, Maximilian Mirwald, Felix Ehret, Carmen Stromberger, Soleiman Fabris Roohani, Katja Bender, Anne Flörcken, Sven Märdian, Daniel Zips, David Kaul, Manish Charan
Sarcoma.2024; 2024: 1. CrossRef
Repeated Radiation Therapy of Recurrent Solitary Fibrous Tumors of the Brain: A Medical Case History Over 20 Years
Anna Carla Piccardo, Sabrina Gurdschinski, Sybille Spieker, Christof Renner, Piotr Czapiewski, Markus Wösle, I. Frank Ciernik
Advances in Radiation Oncology.2024; 9(4): 101426. CrossRef
Intracranial solitary fibrous tumors: Clinical, radiological, and histopathological insights along with review of literature
Adil Aziz Khan, Sana Ahuja, Dipanker Singh Mankotia, Sufian Zaheer
Pathology - Research and Practice.2024; 260: 155456. CrossRef
Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance
V. Matthijs, R. Beckers, C. Vanden Broecke, F. Dedeurwaerdere, J. Van Dorpe, D. Vanhauwaert, G. Hallaert
Acta Neurochirurgica.2024;[Epub] CrossRef
Recurrence of Solitary Fibrous Tumor in the Spinal Cord Following Gross Total and Subtotal Resection: A Case Report of Recurrence 19 Years of Post-total Resection and Systematic Literature Review
Satoka SHIDOH, Kazutoshi HIDA, Yoshitaka ODA, Toru SASAMORI, Prabin SHRESTHA, Jangbo LEE, Satoshi YAMAGUCHI
NMC Case Report Journal.2024; 11: 297. CrossRef
The role of radiotherapy in intracranial hemangiopericytoma/solitary fibrous tumors
Nuri Kaydıhan, Gözde Yazıcı, Petek Erpolat, Serra Kamer, Burak Erdemci, Emine Canyılmaz, Beste Melek Atasoy, Dicle Aslan, Ela Delikgöz Soykut, Enis Özyar, Fatih Demircioğlu, Fazilet Öner Dinçbaş, Meltem Kirli Bolukbas, Ramazan Aksu, Selvi Tabak Dinçer, Ya
Strahlentherapie und Onkologie.2024;[Epub] CrossRef
The Role of Radical Radiotherapy in Sinonasal Myopericytoma: A Case Report and Literature Overview
Anna Merlotti, Stefania Martini, Riccardo Vigna Taglianti, Alessia Reali, Giuseppe Signorini, Silvana Parisi, Francesca De Felice
EMJ Oncology.2023;[Epub] CrossRef
Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study
Marine Lottin, Alexandre Escande, Luc Bauchet, Marie Albert-Thananayagam, Maël Barthoulot, Matthieu Peyre, Mathieu Boone, Sonia Zouaoui, Jacques Guyotat, Guillaume Penchet, Johan Pallud, Henry Dufour, Evelyne Emery, Michel Lefranc, Sébastien Freppel, Houm
Cancers.2023; 15(3): 704. CrossRef
Solitary fibrous tumor of the central nervous system invading and penetrating the skull: A case report
Qiyan Lin, Jiabin Zhu, Xiaofeng Zhang
Oncology Letters.2023;[Epub] CrossRef
Impact of extent of resection and postoperative radiotherapy on survival outcomes in intracranial solitary fibrous tumors: a systematic review and meta-analysis
Sae Min Kwon, Min Kyun Na, Kyu-Sun Choi, Tae Ho Lim, Hyungoo Shin, Juncheol Lee, Heekyung Lee, Wonhee Kim, Youngsuk Cho, Jae Guk Kim, Chiwon Ahn, Bo-Hyoung Jang
Neurosurgical Review.2023;[Epub] CrossRef
Radiotherapy for rare primary brain tumors
E. Mesny, P. Lesueur
Cancer/Radiothérapie.2023; 27(6-7): 599. CrossRef
Complete Resection of a Torcular Herophili Hemangiopericytoma without Sinus Reconstruction: A Case Report and Review of the Literature
Salah-Edine Safi, Julie Godfrain, Herbert Rooijakkers, Frederic Collignon, Mario Ganau
Case Reports in Surgery.2023; 2023: 1. CrossRef
Surgical Management of Craniospinal Axis Solitary Fibrous Tumors: A Single-Institution Case Series and Comprehensive Review of the Literature
Anthony J. Piscopo, A. J. Chowdhury, Nahom Teferi, Sarah Lee, Meron Challa, Michael Petronek, Kathryn Eschbacher, Girish Bathla, John M. Buatti, Patrick Hitchon
Neurosurgery.2023;[Epub] CrossRef
Clinical Features, Management, and Prognostic Factors of Intracranial Solitary Fibrous Tumor
Jingdian Liu, Sisi Wu, Kai Zhao, Junwen Wang, Kai Shu, Ting Lei
Frontiers in Oncology.2022;[Epub] CrossRef
Toward Better Understanding and Management of Solitary Fibrous Tumor
Karineh Kazazian, Elizabeth G. Demicco, Marc de Perrot, Dirk Strauss, Carol J. Swallow
Surgical Oncology Clinics of North America.2022; 31(3): 459. CrossRef
Effect of Different Treatments for Intracranial Solitary Fibrous Tumors: Retrospective Analysis of 31 Patients
Qinghua Li, Wenshuai Deng, Peng Sun
World Neurosurgery.2022; 166: e60. CrossRef
Sixteen-Year Follow-Up in a Cavernous Sinus Hemangiopericytoma: Improved Outcomes over Radiotherapy Advances
Beatrice Detti, Lilia Bardoscia, Antonio Rosario Pisani, Salvatore Cozzi, Manuele Roghi, Paolo Mammucci, Angela Sardaro
Brain Sciences.2022; 12(9): 1209. CrossRef
Solitary Fibrous Tumor of the Jugular Foramen: A Case Report and Review of the Histopathologic Classification
Mallory Raymond, Philip Ryan Elvis, Tiffany Baker, William Alexander Vandergrift, Theodore McRackan
Otology & Neurotology.2022; 43(10): e1208. CrossRef
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
Javier Martin-Broto, Jose L. Mondaza-Hernandez, David S. Moura, Nadia Hindi
Cancers.2021; 13(12): 2913. CrossRef
Intradural Extramedullary Solitary Fibrous Tumor of the Thoracic Spinal Cord
Zachary T Olmsted, Joanna Tabor, Omer Doron, Hossein Hosseini, Daniel Schneider, Ross Green, Samuel J Wahl, Daniel M Scuibba, Randy S D'Amico
Cureus.2021;[Epub] CrossRef

8,810 View
347 Download
20 Web of Science
23 Crossref

A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset: Bum-Sup Jang, In Ah Kim; Cancer Res Treat. 2020;52(2):530-542. Published online November 20, 2019; DOI: https://doi.org/10.4143/crt.2019.440

Abstract PDF Supplementary Material PubReader ePub

Purpose
Combination of radiotherapy and immune checkpoint blockade such as programmed death- 1 (PD-1) or programmed death-ligand 1 (PD-L1) blockade is being actively tested in clinical trial. We aimed to identify a subset of patients that could potentially benefit from this strategy using The Cancer Genome Atlas (TCGA) dataset for glioblastoma (GBM).
Materials and Methods
A total of 399 cases were clustered into radiosensitive versus radioresistant (RR) groups based on a radiosensitivity gene signature and were also stratified as PD-L1 high versus PD-L1 low groups by expression of CD274 mRNA. Differential and integrated analyses with expression and methylation data were performed. CIBERSORT was used to enumerate the immune repertoire that resulted from transcriptome profiles.
Results
We identified a subset of GBM, PD-L1-high-RR group which showed worse survival compared to others. In PD-L1-high-RR, differentially expressed genes (DEG) were highly enriched for immune response and mapped into activation of phosphoinositide 3-kinase–AKT and mitogen-activated protein kinase (MAPK) signaling pathways. Integration of DEG and differentially methylated region identified that the kinase MAP3K8-involved in T-cell receptor signaling was upregulated and BAI1, a factor which inhibits angiogenesis, was silenced. CIBERSORT showed that a higher infiltration of the immune repertoire, which included M2 macrophages and regulatory T cells.
Conclusion
Taken together, PD-L1-high-RR group could potentially benefit from radiotherapy combined with PD-1/PD-L1 blockade and angiogenesis inhibition.

Citations

Citations to this article as recorded by

Clinical Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy: A Systematic Review
Christopher W. Bleaney, Hebatalla Abdelaal, Mark Reardon, Carmel Anandadas, Peter Hoskin, Ananya Choudhury, Laura Forker
Cancers.2024; 16(10): 1942. CrossRef
A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer
Zhuo Chen, Zhuoling Zou, Min Qian, Qin Xu, Guojuan Xue, Juan Yang, Tinglan Luo, Lianjie Hu, Bin Wang
Translational Oncology.2024; 44: 101955. CrossRef
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Hao Lin, Chaxian Liu, Ankang Hu, Duanwu Zhang, Hui Yang, Ying Mao
Journal of Hematology & Oncology.2024;[Epub] CrossRef
PSF-lncRNA interaction as a target for novel targeted anticancer therapies
Ren Liu, Xiaojing Wang, Min Zhou, Jingfang Zhai, Jie Sun
Biomedicine & Pharmacotherapy.2024; 180: 117491. CrossRef
Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers
Charbel Feghaly, Rafka Challita, Hanine Bou Hadir, Tala Mobayed, Tarek Al Bitar, Mohammad Harbi, Hala Ghorayeb, Rana El-Hassan, Larry Bodgi
Biomarker Insights.2024;[Epub] CrossRef
Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity
Zhiru Gao, Qian Zhao, Yiyue Xu, Linlin Wang
Radiation Oncology.2023;[Epub] CrossRef
In Vivo Evaluation of Near-Infrared Fluorescent Probe for TIM3 Targeting in Mouse Glioma
Michael Zhang, Quan Zhou, Chinghsin Huang, Carmel T. Chan, Wei Wu, Gordon Li, Michael Lim, Sanjiv S. Gambhir, Heike E. Daldrup-Link
Molecular Imaging and Biology.2022; 24(2): 280. CrossRef
Relationship between Macrophage and Radiosensitivity in Human Primary and Recurrent Glioblastoma: In Silico Analysis with Publicly Available Datasets
Bum-Sup Jang, In Ah Kim
Biomedicines.2022; 10(2): 292. CrossRef
Optimal management of recurrent and metastatic upper tract urothelial carcinoma: Implications of intensity modulated radiation therapy
Mi Sun Kim, Woong Sub Koom, Jae Ho Cho, Se-Young Kim, Ik Jae Lee
Radiation Oncology.2022;[Epub] CrossRef
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
Daniel Kreatsoulas, Chelsea Bolyard, Bill X. Wu, Hakan Cam, Pierre Giglio, Zihai Li
Journal of Hematology & Oncology.2022;[Epub] CrossRef
The Next Frontier in Health Disparities—A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back
Maria Diaz Rosario, Harpreet Kaur, Erdal Tasci, Uma Shankavaram, Mary Sproull, Ying Zhuge, Kevin Camphausen, Andra Krauze
Biomolecules.2022; 12(9): 1203. CrossRef
Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
Thamiris Becker Scheffel, Nathália Grave, Pedro Vargas, Fernando Mendonça Diz, Liliana Rockenbach, Fernanda Bueno Morrone
Frontiers in Oncology.2021;[Epub] CrossRef
The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
Lu Meng, Jianfang Xu, Ying Ye, Yingying Wang, Shilan Luo, Xiaomei Gong
Frontiers in Immunology.2021;[Epub] CrossRef
Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy
Junjie Shen, Jingfang Liu, Huijun Li, Lu Bai, Zixuan Du, Ruirui Geng, Jianping Cao, Peng Sun, Zaixiang Tang
Radiation Oncology.2021;[Epub] CrossRef
Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on The Cancer Genome Atlas Dataset
Dongjun Dai, Yinglu Guo, Yongjie Shui, Jinfan Li, Biao Jiang, Qichun Wei
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Prognostic Values of Radiosensitivity Genes and CD19 Status in Gastric Cancer: A Retrospective Study Using TCGA Database

Li-Bo Liang, Xin-Yan Huang, He He, Ji-Yan Liu
Pharmacogenomics and Personalized Medicine.2020; Volume 13: 365. CrossRef
Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma
Linzhi Han, Hongjie Shi, Yuan Luo, Wenjie Sun, Shuying Li, Nannan Zhang, Xueping Jiang, Yan Gong, Conghua Xie
Cancer Medicine.2020; 9(24): 9581. CrossRef

7,660 View
261 Download
19 Web of Science
17 Crossref

Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer: Soomin Ahn, Hyun Jeong Kim, Milim Kim, Yul Ri Chung, Eunyoung Kang, Eun-Kyu Kim, Se Hyun Kim, Yu Jung Kim, Jee Hyun Kim, In Ah Kim, So Yeon Park; Cancer Res Treat. 2018;50(4):1418-1432. Published online January 24, 2018; DOI: https://doi.org/10.4143/crt.2017.552

Abstract PDF PubReader ePub

Purpose
Alteration of biomarker status after primary systemic therapy (PST) is occasionally found in breast cancer. This study was conducted to clarify the clinical implications of change of biomarker status in breast cancer patients treated with PST.
Materials and Methods
The pre-chemotherapeutic biopsy and post-chemotherapeutic resection specimens of 442 breast cancer patients who had residual disease after PST were included in this study. The association between changes of biomarker status after PST and clinicopathologic features of tumors, and survival of the patients, were analyzed.
Results
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status changed after PST in 18 (4.1%), 80 (18.1%), and 15 (3.4%) patients,respectively. ER and PR mainly underwent positive to negative conversion,whereas HER2 status underwent negative to positive conversion. Negative conversion of ER and PR status after PST was associated with reduced disease-free survival. Moreover, a decline in the Allred score for PR in post-PST specimens was significantly associated with poor clinical outcome of the patients. HER2 change did not have prognostic significance. In multivariate analyses, negative PR status after PST was found to be an independent adverse prognostic factor in the whole patient group, in the adjuvant endocrine therapy-treated subgroup, and also in pre-PST PR positive subgroup.
Conclusion
ER and HER2 status changed little after PST, whereas PR status changed significantly. In particular, negative conversion of PR status was revealed as a poor prognostic indicator, suggesting that re-evaluation of basic biomarkers is mandatory in breast cancer after PST for proper management and prognostication of patients.

Citations

Citations to this article as recorded by

Changing the phenotype of breast cancer in the process treatment: literature review
M. S. Shvedsky, R. I. Tamrazov, T. P. Shevlyukova, L. A. Bakhova
Surgery and Oncology.2024; 13(4): 50. CrossRef
HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen
Pathology.2024; 56(3): 334. CrossRef
NGS mutational status on first diagnostic tissue, liquid biopsy and mastectomy in G2–G3 breast cancer
Carmen Maria Ardeleanu, Maria Victoria Olinca , Cristian Gabriel Viişoreanu , Horaţiu Alin Mureşan , Adriana Tecuceanu-Vulpe , Georgiana Manole , Iulia Elena Gune , Bianca Gălăţeanu , Andreea-Corina Ilie-Petrov
Romanian Journal of Morphology and Embryology.2024; 65(2): 195. CrossRef
Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities—A State-of-the-Art Review
Dominika Kunachowicz, Karolina Kłosowska, Natalia Sobczak, Marta Kepinska
Nanomaterials.2024; 14(17): 1424. CrossRef
Establishment and evaluation of digital PCR methods for HER2 copy number variation in breast cancer
Xia Wang, Dechun Xing, Zheng Liu, Yujing Zhang, Bo Cheng, Suozhu Sun, Qingtao Wang, Lianhua Dong
Analytical and Bioanalytical Chemistry.2023; 415(4): 725. CrossRef
Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients
Yang He, Jing Zhang, Hui Chen, Ying Zhou, Liping Hong, Yue Ma, Nannan Chen, Weipeng Zhao, Zhongsheng Tong
Frontiers in Surgery.2023;[Epub] CrossRef
Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients
Jiaqi Bo, Baohua Yu, Rui Bi, Xiaoli Xu, Yufan Cheng, Xiaoyu Tu, Qianming Bai, Wentao Yang, Ruohong Shui
Clinical Breast Cancer.2023; 23(4): 436. CrossRef
Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites
Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi
Bulletin du Cancer.2023; 110(12): 1301. CrossRef
HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review
Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen
World Journal of Clinical Cases.2022; 10(1): 260. CrossRef
Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer
L. V. Bolotina, A. L. Kornietskaya, A. A. Kachmazov, N. S. Prizova, A. A. Paichadze, T. V. Ustinova, T. I. Deshkina, S. F. Evdokimova
Meditsinskiy sovet = Medical Council.2022; (9): 179. CrossRef
Machine learning on MRI radiomic features: identification of molecular subtype alteration in breast cancer after neoadjuvant therapy
Hai-Qing Liu, Si-Ying Lin, Yi-Dong Song, Si-Yao Mai, Yue-dong Yang, Kai Chen, Zhuo Wu, Hui-Ying Zhao
European Radiology.2022; 33(4): 2965. CrossRef
Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
Mengping Long, Chong You, Qianqian Song, Lina Hu, Zhaorong Guo, Qian Yao, Wei Hou, Wei Sun, Baosheng Liang, Xiao-Hua Zhou, Yiqiang Liu, Taobo Hu
Life.2022; 13(1): 74. CrossRef
The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
M G Davey, É J Ryan, P J Folan, N O’Halloran, M R Boland, M K Barry, K J Sweeney, C M Malone, R J McLaughlin, M J Kerin, A J Lowery
BJS Open.2021;[Epub] CrossRef
Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer
Yul Ri Chung, Ji Won Woo, Soomin Ahn, Eunyoung Kang, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, Se Hyun Kim, Jee Hyun Kim, So Yeon Park
Scientific Reports.2021;[Epub] CrossRef
Enriched transcriptome analysis of laser capture microdissected populations of single cells to investigate intracellular heterogeneity in immunostained FFPE sections
Sarah M. Hammoudeh, Arabella M. Hammoudeh, Thenmozhi Venkatachalam, Surendra Rawat, Manju N. Jayakumar, Mohamed Rahmani, Rifat Hamoudi
Computational and Structural Biotechnology Journal.2021; 19: 5198. CrossRef
Lost but Not Least—Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer
Michał Kunc, Marta Popęda, Wojciech Biernat, Elżbieta Senkus
Cancers.2021; 13(19): 4755. CrossRef
Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience
Saverio Coiro, Elisa Gasparini, Giuseppe Falco, Giacomo Santandrea, Moira Foroni, Giulia Besutti, Valentina Iotti, Roberto Di Cicilia, Monica Foroni, Simone Mele, Guglielmo Ferrari, Giancarlo Bisagni, Moira Ragazzi
Diagnostics.2021; 11(12): 2249. CrossRef
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
Journal of Pathology and Translational Medicine.2020; 54(1): 34. CrossRef
Effect of neoadjuvant therapy on breast cancer biomarker profile
Laura Rey-Vargas, Juan Carlos Mejía-Henao, María Carolina Sanabria-Salas, Silvia J. Serrano-Gomez
BMC Cancer.2020;[Epub] CrossRef
Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value
Ji Won Woo, Yul Ri Chung, Soomin Ahn, Eunyoung Kang, Eun-Kyu Kim, Se Hyun Kim, Jee Hyun Kim, In Ah Kim, So Yeon Park
Journal of Breast Cancer.2019; 22(3): 439. CrossRef

10,318 View
198 Download
19 Web of Science
20 Crossref

A Novel Prognostic Nomogram for Predicting Risks of Distant Failure in Patients with Invasive Breast Cancer Following Postoperative Adjuvant Radiotherapy: Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, In Ah Kim; Cancer Res Treat. 2018;50(4):1140-1148. Published online December 7, 2017; DOI: https://doi.org/10.4143/crt.2017.508

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to identify predictors for distant metastatic behavior and build a related prognostic nomogram in breast cancer.
Materials and Methods
A total of 1,181 patients with non-metastatic breast cancer between 2003 and 2011 were analyzed. To predict the probability of distant metastasis, a nomogram was constructed based on prognostic factors identified using a Cox proportional hazards model.
Results
The 7-year overall survival and 5-year post-progression survival of locoregional versus distant recurrence groups were 67.6% versus 39.1% (p=0.027) and 54.2% versus 33.5% (p=0.043), respectively. Patients who developed distant metastasis showed early and late mortality risk peaks within 3 and after 5 years of follow-up, respectively, but a broad and low risk increment was observed in other patients with locoregional relapse. In multivariate analysis of distant metastasis-free interval, age (≥ 45 years vs. < 45 years), molecular subtypes (luminal A vs. luminal B, human epidermal growth receptor 2, and triple negative), T category (T1 vs. T2-3 and T4), and N category (N0 vs. N1 and N2-3) were independently associated (p < 0.05 for all). Regarding the significant factors, a well-validated nomogram was established (concordance index, 0.812). The risk score level of patients with initial brain failure was higher than those of non-brain sites (p=0.029).
Conclusion
The nomogram could be useful for predicting the individual probability of distant recurrence in breast cancer. In high-risk patients based on the risk scores, more aggressive systemic therapy and closer surveillance for metastatic failure should be considered.

Citations

Citations to this article as recorded by

Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning
Audrey Shiner, Alex Kiss, Khadijeh Saednia, Katarzyna J. Jerzak, Sonal Gandhi, Fang-I Lu, Urban Emmenegger, Lauren Fleshner, Andrew Lagree, Marie Angeli Alera, Mateusz Bielecki, Ethan Law, Brianna Law, Dylan Kam, Jonathan Klein, Christopher J. Pinard, Ale
Genes.2023; 14(9): 1768. CrossRef
Nomograms for Predicting Specific Distant Metastatic Sites and Overall Survival of Breast Invasive Ductal Carcinoma Patients After Surgery: A Large Population-Based Study
Yuqian Feng, Yiting Zhang, Yuying Xiang, Kaibo Guo, Huimin Jin, Shanming Ruan, Zhuoya Guan
Frontiers in Surgery.2022;[Epub] CrossRef
Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer
Jing Yang, Shu-Nan Qi, Hui Fang, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Wei-Hu Wang, Yong Yang, Yu Tang, Hua Ren, Bo Chen, Ning-Ning Lu, Yuan Tang, Ning Li, Hao Jing, Shu-Lian Wang, Ye-Xiong Li
The Breast.2021; 58: 72. CrossRef
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Rika Kouhashi, Akimichi Yabumoto, Sae Ishihara, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira
BMC Women's Health.2021;[Epub] CrossRef
Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
Inmaculada Beato Tortajada, Carlos Ferrer Albiach, Virginia Morillo Macias
The Breast.2021; 60: 255. CrossRef
Prognostic Factors and Nomograms to Predict Overall and Cancer-Specific Survival for Children with Wilms’ Tumor
Fucai Tang, Hanbin Zhang, Zechao Lu, Jiamin Wang, Chengwu He, Zhaohui He
Disease Markers.2019; 2019: 1. CrossRef
Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model
Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang
Cancer Research and Treatment.2018; 50(4): 1260. CrossRef

9,252 View
233 Download
11 Web of Science
7 Crossref

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea: Byung Sup Kim, Ho Jun Seol, Do-Hyun Nam, Chul-Kee Park, Il Han Kim, Tae Min Kim, Jeong Hoon Kim, Young Hyun Cho, Sang Min Yoon, Jong Hee Chang, Seok-Gu Kang, Eui Hyun Kim, Chang-Ok Suh, Tae-Young Jung, Kyung-Hwa Lee, Chae-Yong Kim, In Ah Kim, Chang-Ki Hong, Heon Yoo, Jin Hee Kim, Shin-Hyuk Kang, Min Kyu Kang, Eun-Young Kim, Sun-Hwan Kim, Dong-Sup Chung, Sun-Chul Hwang, Joon-Ho Song, Sung Jin Cho, Sun-Il Lee, Youn-Soo Lee, Kook-Jin Ahn, Se Hoon Kim, Do Hun Lim, Ho-Shin Gwak, Se-Hoon Lee, Yong-Kil Hong; Cancer Res Treat. 2017;49(1):193-203. Published online June 27, 2016; DOI: https://doi.org/10.4143/crt.2015.473

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample.
Materials and Methods
A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively.
Results
After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients,respectively. The methylation status of O⁶-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period.
Conclusion
Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.

Citations

Citations to this article as recorded by

Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection
Masayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, Yukinori Akiyama, Takaaki Beppu, Shigeo Ohba, Toshiyuki Enomoto, Takahiro Ono, Yuta Mitobe, Mitsuto Hanihara, Yohei Mineharu, Joji Ishida, Kenichiro Asano, Yasuyuki Yoshida, Manabu Natsumeda, Sadahir
International Journal of Clinical Oncology.2025; 30(1): 51. CrossRef
Letter to the Editor Regarding Cerebral Blood Flow Role in Delineating Treatment Effect from True Tumor Progression in Glioblastoma Multiforme
Inibehe Ime Okon, Tolulope Judah Gbayisomore, Samuel Berchi Kankam, Mohammad Jalloh
World Neurosurgery.2024; 186: 269. CrossRef
NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park
Acta Neuropathologica Communications.2024;[Epub] CrossRef
The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1)
Min-Sung Kim, Se-Il Go, Chan Woo Wee, Min Ho Lee, Seok-Gu Kang, Kyeong-O Go, Sae Min Kwon, Woohyun Kim, Yun-Sik Dho, Sung-Hye Park, Youngbeom Seo, Sang Woo Song, Stephen Ahn, Hyuk-Jin Oh, Hong In Yoon, Sea-Won Lee, Joo Ho Lee, Kyung Rae Cho, Jung Won Choi
Brain Tumor Research and Treatment.2023; 11(2): 123. CrossRef
Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges
Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Kazuki Taoka, Mariko Tanaka, Reiko Matsuura, Shota Tanaka, Nobuhito Saito
BMC Neurology.2023;[Epub] CrossRef
Glioma angiogenesis is boosted by ELK3 activating the HIF-1$$alpha$$/VEGF-A signaling axis
Mou Yueyang, Hu Yaqin, Xue Guolian, Zhao Wenjian, Jiao Yang, Li Chen, Cao Haiyan, Chao Min, Deng Jianping, Dai Penggao, Zhu Hongli, Wang Liang
BMC Cancer.2023;[Epub] CrossRef
Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
Kihwan Hwang, Junhyung Kim, Seok‐Gu Kang, Tae‐Young Jung, Jeong Hoon Kim, Se‐Hyuk Kim, Shin‐Hyuk Kang, Yong‐Kil Hong, Tae Min Kim, Yu Jung Kim, Byung Se Choi, Jong Hee Chang, Chae‐Yong Kim
Cancer Medicine.2022; 11(2): 371. CrossRef
Prognostic Value and Risk Factors of Treatment-Related Lymphopenia in Malignant Glioma Patients Treated With Chemoradiotherapy: A Systematic Review and Meta-Analysis
Yongchao Zhang, Shichao Chen, Hualei Chen, Shanshan Chen, Zhen Li, Enshan Feng, Wei Li
Frontiers in Neurology.2022;[Epub] CrossRef
PrACTiC: A Predictive Algorithm for Chemoradiotherapy-Induced Cytopenia in Glioblastoma Patients
Alireza Amouheidari, Zahra Alirezaei, Stefan Rauh, Masoud Hassanpour, Ozkan Kanat
Journal of Oncology.2022; 2022: 1. CrossRef
Relapsing High—Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options
Maria Chiara Lo Greco, Roberto Milazzotto, Rocco Luca Emanuele Liardo, Grazia Acquaviva, Madalina La Rocca, Roberto Altieri, Francesco Certo, Giuseppe Maria Barbagallo, Antonio Basile, Pietro Valerio Foti, Stefano Palmucci, Stefano Pergolizzi, Antonio Pon
Brain Sciences.2022; 12(4): 416. CrossRef
Effect of Choline Alphoscerate on the Survival of Glioblastoma Patients: A Retrospective, Single-Center Study
Yeong Jin Kim, Tae-Kyu Lee, Myung-Giun Noh, Tae-Young Jung, In-Young Kim, Shin Jung, Kyung-Hwa Lee, Kyung-Sub Moon
Journal of Clinical Medicine.2022; 11(20): 6052. CrossRef
Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging
Matthew L. White, Yan Zhang, Syed A. Jaffar Kazmi, Michele Aizenberg, Nicole Shonka, Fang Yu, Adams Kusi Appiah, Michael C. Burger
PLOS ONE.2021; 16(1): e0244275. CrossRef
Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
Alexandra McAleenan, Claire Kelly, Francesca Spiga, Ashleigh Kernohan, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Tomos Robinson, Sebastian Brandner, Claire L Faulkner, Christopher Wragg, Sarah Jefferies, Amy Howell, Luke Vale, Julian P T Higgins, Kathr
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Mixed malignant glioblastoma and schwannoma in spinal cord with metachronous ependymoma: A case report
Mostafa Farzin, Mohamadreza Hajiabadi, Mohammad Rahmani, Kasra Kolahdouzan
Clinical Case Reports.2021;[Epub] CrossRef
Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study
Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert
CNS Oncology.2021;[Epub] CrossRef
A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
Fahimeh Attarian, Farzad Taghizadeh-Hesary, Azar Fanipakdel, Seyed Alireza Javadinia, Pejman Porouhan, Babak PeyroShabany, Danial Fazilat-Panah
Frontiers in Oncology.2021;[Epub] CrossRef
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
Chae-Yong Kim, Sun Ha Paek, Do-hyun Nam, Jong-Hee Chang, Yong-Kil Hong, Jeong Hoon Kim, Oh Lyong Kim, Se-Hyuk Kim
Journal of Neuro-Oncology.2020; 146(3): 399. CrossRef
Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy
Qiang Wang, Fengxia Xiao, Fei Qi, Xiaopeng Song, Yonghua Yu
Cancer Research and Treatment.2020; 52(2): 586. CrossRef
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
Maria B. Garcia-Fabiani, Maria Ventosa, Andrea Comba, Marianela Candolfi, Alejandro J. Nicola Candia, Mahmoud S. Alghamri, Padma Kadiyala, Stephen Carney, Syed M. Faisal, Anna Schwendeman, James J. Moon, Lindsay Scheetz, Joerg Lahann, Ava Mauser, Pedro R.
Expert Opinion on Investigational Drugs.2020; 29(7): 659. CrossRef
Long Intergenic Non-Protein Coding RNA 1094 Promotes Initiation and Progression of Glioblastoma by Promoting microRNA-577-Regulated Stabilization of Brain-Derived Neurotrophic Factor

Xiaoyan Dong, Xiuxin Fu, Miao Yu, Zengfen Li
Cancer Management and Research.2020; Volume 12: 5619. CrossRef
SNHG7 Facilitates Glioblastoma Progression by Functioning as a Molecular Sponge for MicroRNA-449b-5p and Thereby Increasing MYCN Expression
Yaogang Chen, Shaoyong Yuan, Tieying Ning, Huiqing Xu, Bo Guan
Technology in Cancer Research & Treatment.2020;[Epub] CrossRef
Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres
Hyeong-Cheol Oh, Jin-Kyoung Shim, Junseong Park, Ji-Hyun Lee, Ran Joo Choi, Nam Hee Kim, Hyun Sil Kim, Ju Hyung Moon, Eui Hyun Kim, Jong Hee Chang, Jong In Yook, Seok-Gu Kang
Journal of Cancer Research and Clinical Oncology.2020; 146(11): 2817. CrossRef
Clinical Characteristics of High-Grade Glioma with Primary Leptomeningeal Seeding at Initial Diagnosis in a Single Center Study
Ji-Eyon Kwon, Kihwan Hwang, Kyeong-O Go, Chan Woo Wee, In Ah Kim, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Jung Ho Han, Chae-Yong Kim
Brain Tumor Research and Treatment.2020; 8(2): 77. CrossRef
A Longitudinal Study of Lipid Peroxidation and Symptom Clusters in Patients With Brain Cancers
Sanghee Kim
Nursing Research.2018; 67(5): 387. CrossRef
Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions
Yong Wonn Kwon, Won-Jin Moon, Mina Park, Hong Gee Roh, Young Cho Koh, Sang Woo Song, Jin Woo Choi
Investigative Magnetic Resonance Imaging.2018; 22(3): 158. CrossRef
Notch1ablation radiosensitizes glioblastoma cells
Na Han, Guangyuan Hu, Lei Shi, Guoxian Long, Lin Yang, Qingsong Xi, Qiuyun Guo, Jianhua Wang, Zhen Dong, Mengxian Zhang
Oncotarget.2017; 8(50): 88059. CrossRef
Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system
Haihui Jiang, Yong Cui, Junmei Wang, Song Lin
Oncotarget.2017; 8(12): 20354. CrossRef

15,940 View
314 Download
24 Web of Science
27 Crossref

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma: Yongjun Cha, Yu Jung Kim, Se-Hoon Lee, Tae-Min Kim, Seung Hong Choi, Dong-Wan Kim, Chul-Kee Park, Il Han Kim, Jee Hyun Kim, Eunhee Kim, Byungse Choi, Chae-Yong Kim, In Ah Kim, Dae Seog Heo; Cancer Res Treat. 2017;49(1):129-140. Published online May 18, 2016; DOI: https://doi.org/10.4143/crt.2015.466

Abstract PDF PubReader ePub

Purpose
Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established.
Materials and Methods
Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institutions were identified. Patients who continued bevacizumab until tumor progression were enrolled in a late discontinuation (LD) group, while those who stopped bevacizumab before tumor progression were enrolled in an early discontinuation (ED) group. Landmark analyses were performed at weeks 9, 18, and 26 for comparison of patient survival between the two groups.
Results
Among 89 assessable patients, 62 (69.7%) and 27 (30.3%) patients were categorized as the LD and ED groups, respectively. According to landmark analysis, survival times from weeks 9, 18, and 26 were not significantly different between the two groups in the overall population. However, the LD group showed a trend toward increased survival compared to the ED group among responders. In the ED group, the median time from discontinuation to disease progression was 11.4 weeks, and none of the patients showed a definite rebound phenomenon. Similar median survival times after disease progression were observed between groups (14.4 weeks vs. 15.7 weeks, p=0.251). Of 83 patients, 38 (45.8%) received further therapy at progression, and those who received further therapy showed longer survival in both the LD and ED groups.
Conclusion
In recurrent malignant glioma, duration of bevacizumab was not associated with survival time in the overall population. However, ED of bevacizumab in responding patients might be associated with decreased survival.

Citations

Citations to this article as recorded by

The Vascular Microenvironment in Glioblastoma: A Comprehensive Review
Alejandra Mosteiro, Leire Pedrosa, Abel Ferrés, Diouldé Diao, Àngels Sierra, José Juan González
Biomedicines.2022; 10(6): 1285. CrossRef
Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors
Tiziana Annese, Mariella Errede, Antonio d’Amati, Michelina De Giorgis, Loredana Lorusso, Roberto Tamma, Domenico Ribatti
Diagnostics.2022; 12(12): 3120. CrossRef
Identification of diverse tumor endothelial cell populations in malignant glioma
Jeff C Carlson, Manuel Cantu Gutierrez, Brittney Lozzi, Emmet Huang-Hobbs, Williamson D Turner, Burak Tepe, Yiqun Zhang, Alexander M Herman, Ganesh Rao, Chad J Creighton, Joshua D Wythe, Benjamin Deneen
Neuro-Oncology.2021; 23(6): 932. CrossRef
Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy
Charlotte Bronnimann, Cristina Izquierdo, Stéphanie Cartalat, Laure Thomas, Bastien Joubert, Laura Delpech, Marc Barritault, David Meyronet, Jérôme Honnorat, François Ducray
Journal of Neuro-Oncology.2018; 138(1): 141. CrossRef

10,309 View
181 Download
5 Web of Science
4 Crossref

Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization: Jin Ho Kim, Sung Ho Moon, Mina No, Jae Jin Kim, Eun Jung Choi, Bong Jun Cho, Jae Sung Kim, Il Han Kim, In Ah Kim; Cancer Res Treat. 2016;48(3):1130-1140. Published online November 17, 2015; DOI: https://doi.org/10.4143/crt.2015.206

Abstract PDF Supplementary Material PubReader ePub

Purpose
Histone deacetylase (HDAC) inhibitors radiosensitize tumor cells. To elucidate mechanisms underlying radiosensitization by HDAC inhibition, understanding of differential contributions of HDAC isotypes is needed. The aim of this study was to investigate involvement of known HDAC isotypes in modulation of cellular radiosensitivity. Materials and Methods Because pharmacologic HDAC inhibitors lack isotype-specificity, RNA interference against 11 HDAC isotypes was used to inhibit HDAC in an isotype-specific manner. Radiation cell survival was evaluated using a clonogenic assay in SQ20B cells transfected with small interfering RNA specifically targeting HDAC isotypes. Immunocytochemistry was performed for detection of γH2AX foci. Protein expression was measured using Western blotting.
Results
Among 11 HDAC isotypes tested, specific inhibition of 7 isotypes (HDAC1, HDAC3, HDAC4, HDAC6, HDAC7, HDAC10, and HDAC11) enhanced radiation lethality in SQ20B cells. Radiosensitization by inhibition of these HDAC isotypes was accompanied by delay of DNA double strand break repair. Radiosensitivity of SQ20B cells was not altered by selective inhibition of the remaining four isotypes (HDAC2, HDAC5, HDAC8, and HDAC9). Inhibition of HDAC isotypes resulted in downregulation of various proteins involved in pro-survival and DNA damage repair pathways. Conclusion Isotype-specificity exists in HDAC inhibition-induced radiosensitization. Different HDAC isotypes are differentially involved in modulation of cellular radiosensitivity.

Citations

Citations to this article as recorded by

Effects of a novel HDAC6-selective inhibitor’s radiosensitization on cancer cells
Huixiao Hu, Qi Wang, Yuni Zhang, Shuhua Yang, Aihua Shen, Junfang Yan, Denggao Zhao, Burong Hu
Molecular Biology Reports.2024;[Epub] CrossRef
HDAC11: A novel target for improved cancer therapy
Yan Liu, Xuechao Tong, Weina Hu, Da Chen
Biomedicine & Pharmacotherapy.2023; 166: 115418. CrossRef
Histone deacetylase 10, a potential epigenetic target for therapy
Fajuan Cheng, Bin Zheng, Jianwei Wang, Guiting Zhao, Zhongshun Yao, Zhihong Niu, Wei He
Bioscience Reports.2021;[Epub] CrossRef
Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1
Hoon Sik Choi, Jin Hyun Kim, Si Jung Jang, Jeong Won Yun, Ki Mun Kang, Hojin Jeong, In Bong Ha, Bae Kwon Jeong
Cancer Research and Treatment.2021; 53(3): 685. CrossRef
HDAC11: a rising star in epigenetics
Shan-Shan Liu, Fei Wu, Yue-Mei Jin, Wei- Qin Chang, Tian-Min Xu
Biomedicine & Pharmacotherapy.2020; 131: 110607. CrossRef
Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim
Cancer Research and Treatment.2019; 51(2): 696. CrossRef
Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA
Maxwell T. Laws, Robin E. Bonomi, Swatabdi Kamal, David J. Gelovani, Jeremy Llaniguez, Shreya Potukutchi, Xin Lu, Thomas Mangner, Juri G. Gelovani
Scientific Reports.2019;[Epub] CrossRef
Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP
Sung-Won Shin, Changhoon Choi, Ga-Haeng Lee, Arang Son, Su-Hyeon Kim, Hee Chul Park, Ines Batinic-Haberle, Won Park
Antioxidants & Redox Signaling.2017; 27(14): 1067. CrossRef
MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling
Taeryool Koo, Bong Jun Cho, Dan Hyo Kim, Ji Min Park, Eun Jung Choi, Hans H. Kim, David J Lee, In Ah Kim
Oncotarget.2017; 8(39): 65457. CrossRef
Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
Alokta Chakrabarti, Jelena Melesina, Fiona R Kolbinger, Ina Oehme, Johanna Senger, Olaf Witt, Wolfgang Sippl, Manfred Jung
Future Medicinal Chemistry.2016; 8(13): 1609. CrossRef

12,478 View
153 Download
10 Web of Science
10 Crossref

Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer: Jeanny Kwon, Keun-Yong Eom, In Ah Kim, Jae-Sung Kim, Young-Beom Kim, Jae Hong No, Kidong Kim; Cancer Res Treat. 2016;48(2):632-640. Published online July 14, 2015; DOI: https://doi.org/10.4143/crt.2015.085

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to compare the prognostic efficacy of the number and location of positive lymph nodes (LN), LN ratio (LNR), and log odds of positive LNs (LODDs) in highrisk cervical cancer treated with radical surgery and adjuvant treatment. Materials and Methods Fifty high-risk patients who underwent radical hysterectomy and pelvic node dissection followed by adjuvant treatment were analyzed retrospectively. The patients had International Federation of Gynecology and Obstetrics (FIGO) stage IA2-IIB. Upper LN is defined as common iliac or higher LN, and LNR is the ratio of positive LNs to harvested LNs. LODDs is log odds between positive LNs and negative LNs. Radiotherapy was delivered to the whole pelvis with median 50.4 Gy/28 Fx± to the para-aortic regions. Platinum-based chemotherapy was used in most patients (93%). The median follow-up duration was 80 months. Results The 5-year disease-free survival (DFS) rate was 76.1%, and the overall survival (OS) rate was 86.4%. Treatment failure occurred in 11 patients, and distant failure (DF) was the dominant pattern (90.9%). In univariate analysis, significantly lower DFSwas observed in patients with perineural invasion, ≥ 2 LN metastases, LNR ≥ 10%, upper LN metastasis, and ≥ –1.05 LODDs. In multivariate analysis, ≥ –1.05 LODDs was the only significant factor for DFS (p=0.011). Of patients with LODDs ≥ –1.05, 40.9% experienced DF. LODDs was the only significant prognostic factor for OS as well (p=0.006). Conclusion LODDs ≥ –1.05 was the only significant prognostic factor for both DFS and OS. In patients with LODDs ≥ –1.05, intensified chemotherapy might be required, considering the high rate of DF.

Citations

Citations to this article as recorded by

Perineural invasion in cervical cancer: A multicenter retrospective study
Xiaolin Chen, Hui Duan, Hongwei Zhao, Fangjie He, Lu Yin, Yueping Liu, Lixia Wang, Chunlin Chen
European Journal of Surgical Oncology.2024; 50(6): 108313. CrossRef
Recent Advances in Cervical Cancer Management: A Review on Novel Prognostic Factors in Primary and Recurrent Tumors
Angela Santoro, Frediano Inzani, Giuseppe Angelico, Damiano Arciuolo, Emma Bragantini, Antonio Travaglino, Michele Valente, Nicoletta D’Alessandris, Giulia Scaglione, Stefania Sfregola, Alessia Piermattei, Federica Cianfrini, Paola Roberti, Gian Franco Za
Cancers.2023; 15(4): 1137. CrossRef
Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis
Jianying Yi, Zhili Liu, Lu Wang, Xingxin Zhang, Lili Pi, Chunlei Zhou, Hong Mu
Frontiers in Oncology.2022;[Epub] CrossRef
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review
Fengying Qin, Huiting Pang, Tao Yu, Yahong Luo, Yue Dong
Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
The Log Odds of Positive Lymph Nodes Predict Survival of Advanced-Stage Endometrial Cancer: A Retrospective Analysis of 3230 Patients in the Surveillance, Epidemiology, and End Results Database
Christopher G. Smith, Quan Chen, Bin Huang, Rachel W. Miller, Christopher P. DeSimone, Charles S. Dietrich, Frederick R. Ueland, Holly H. Gallion, Edward J. Pavlik, John R. van Nagell, Lauren A. Baldwin Branch
Journal of Gynecologic Surgery.2022; 38(4): 278. CrossRef
The extent of aortic lymphadenectomy in locally advanced cervical cancer impacts on survival
Antoni Llueca, Javier Escrig, Antonio Gil-Moreno, Virginia Benito, Alicia Hernández, Berta Díaz-Feijoo
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Lymph Node Ratio Is a Strong Prognostic Factor in Patients with Early-Stage Cervical Cancer Undergoing Minimally Invasive Radical Hysterectomy
Se Ik Kim, Tae Hun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Taek Sang Lee, Hye Won Jeon, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
Yonsei Medical Journal.2021; 62(3): 231. CrossRef
The role of lymph nodes in cervical cancer: incidence and identification of lymph node metastases—a literature review
Ester P. Olthof, Maaike A. van der Aa, Judit A. Adam, Lukas J. A. Stalpers, Hans H. B. Wenzel, Jacobus van der Velden, Constantijne H. Mom
International Journal of Clinical Oncology.2021; 26(9): 1600. CrossRef
Prognostic implications of ENE and LODDS in relation to lymph node-positive colorectal cancer location
Tengfei Li, Yan Yang, Weidong Wu, Zhongmao Fu, Feichi Cheng, Jiahui Qiu, Qi Li, Kundong Zhang, Zai Luo, Zhengjun Qiu, Chen Huang
Translational Oncology.2021; 14(11): 101190. CrossRef
The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy
Koray Aslan, Mehmet Mutlu Meydanli, Murat Oz, Yusuf Aytac Tohma, Ali Haberal, Ali Ayhan
Journal of Gynecologic Oncology.2020;[Epub] CrossRef
Radiomic signature as a predictive factor for lymph node metastasis in early‐stage cervical cancer
Yangyang Kan, Di Dong, Yuchen Zhang, Wenyan Jiang, Nannan Zhao, Lu Han, Mengjie Fang, Yali Zang, Chaoen Hu, Jie Tian, Chunming Li, Yahong Luo
Journal of Magnetic Resonance Imaging.2019; 49(1): 304. CrossRef
The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04)
Jeanny Kwon, Keun-Young Eom, Young Seok Kim, Won Park, Mison Chun, Jihae Lee, Yong Bae Kim, Won Sup Yoon, Jin Hee Kim, Jin Hwa Choi, Sei Kyung Chang, Bae Kwon Jeong, Seok Ho Lee, Jihye Cha
Cancer Research and Treatment.2018; 50(3): 964. CrossRef
Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer
Weiye Deng, Ting Xu, Yifan Wang, Yujin Xu, Pei Yang, Daniel Gomez, Zhongxing Liao
Lung Cancer.2018; 122: 60. CrossRef
Prognostic significance of lymph node ratio in node-positive cervical cancer patients
Ji Hyeon Joo, Young Seok Kim, Joo-Hyun Nam
Medicine.2018; 97(30): e11711. CrossRef
Prognostic Value of Fluorine-18 Fluorodeoxyglucose Uptake of Bone Marrow on Positron Emission Tomography/Computed Tomography for Prediction of Disease Progression in Cervical Cancer
Jeong Won Lee, Seob Jeon, Seong Taek Mun, Sang Mi Lee
International Journal of Gynecological Cancer.2017; 27(4): 776. CrossRef

12,007 View
90 Download
24 Web of Science
15 Crossref

Objective Measurement of Cosmetic Outcomes of Breast Conserving Therapy Using BCCT.core: Tosol Yu, Keun-Yong Eom, Na Young Jang, Kyung Su Kim, Tae Ryool Koo, Jeanny Kwon, Byoung Hyuck Kim, Eunyoung Kang, Sung-Won Kim, Jae-Sung Kim, In Ah Kim; Cancer Res Treat. 2016;48(2):491-498. Published online June 22, 2015; DOI: https://doi.org/10.4143/crt.2015.088

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study is to evaluate objective cosmetic outcomes and factors related to breast-conserving therapy (BCT) using the BCCT.core software.
Materials and Methods
Fifty-one patients who received BCT with informed consent were evaluated using the BCCT.core software. Patients were divided into two groups based on the BCCT score: excellent or good (n=42) vs. fair or poor (n=9). Analysis of clinical factors was performed to determine factors affecting cosmetic outcomes.
Results
The objective cosmetic outcome of BCT measured using the BCCT.core software was excellent in 10% of patients, good in 72%, and fair in 18%. None of the patients were classified as poor outcome. Tumor characteristics, systemic adjuvant therapy (chemotherapy and hormonal therapy), and radiation dose or energy of electron boost did not show correlation with the score measured by the BCCT.core program (p > 0.05). In univariate analysis, maximum dose within the breast (Dmax), width of tangential field, and excised tumor volume were smaller in patients with excellent or good by the BCCT.core compared to those with fair or poor (Dmax, 110.2±1.5% vs. 111.6±1.7%, p=0.019; width of tangential field, 8.0±1.1 cm vs. 8.6±0.7 cm, p=0.034; excised tumor volume, 64.0±35.8 cm3 vs. 95.3±54.4 cm3, p=0.067). In multivariate analysis, only Dmax was a significant factor for breast cosmetic outcome with a risk ratio of 1.697 (95% confidence interval, 1.006 to 2.863; p=0.047).
Conclusion
Objective measurement of cosmetic outcome of BCT using the BCCT.core software was feasible. The cosmetic outcome of BCT may be affected by the maximum dose within the breast.

Citations

Citations to this article as recorded by

Impact of autologous breast reconstruction on bra fit
Yen-Tung Liu, Novera H. Khan, Mary Catherine Bordes, Gregory P. Reece, Ashleigh M. Francis, Tzuan A. Chen, Karen Bravo, Mia K. Markey
Supportive Care in Cancer.2024;[Epub] CrossRef
Easy Anthropometric Measurements Are Representative of Baseline Values of Breast Q Values in Asymptomatic Women
Giuseppe Catanuto, Nicola Rocco, Concetta G. Fichera, Ada Cinquerrui, Martina Rapisarda, Paolo Chiodini, Francesca Magnoni, Patrizia Dorangricchia, Valeria Sebri, Gabriella Pravettoni, Maurizio Bruno Nava, Francesco Caruso
Healthcare.2024; 12(2): 268. CrossRef
Outcomes of reconstructive techniques in breast cancer using BCCT. core software
Sevgi Kurt, Ahmet Serkan İlgün, Enver Özkurt, Gürsel Soybir, Gül Alço, Çağlar Ünal, Filiz Elbüken Çelebi, Tomris Duymaz, Tuğba Kayan Tapan, Naziye Ak, Çetin Ordu, Vahit Özmen
World Journal of Surgical Oncology.2024;[Epub] CrossRef
Evaluating intra and inter-observer bias in the cosmetic rating for random vs. serial assessment of breast photographs
Preeti Belani, Rima Pathak, Shraddha Kenekar, Gaurika Pokale, Pallavi Rane, Ashwini Chalke, Tabassum Wadasadawala
The Royal College of Radiologists Open.2024; 2: 100152. CrossRef
Comparison of Postoperative Breast Asymmetry Using Vectra 3D Imaging in Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction
Seung-Ho Choi, Sang-Oh Lee, Kyu-Jin Chung, Il-Kug Kim, Jun-Ho Lee
Journal of Clinical Medicine.2024; 13(23): 7486. CrossRef
Long-term Efficacy and Cosmetic Outcomes of Partial-breast Irradiation Using Multicatheter Interstitial Brachytherapy for Breast-conserving Therapy
Kazuhiko SATO, Hiromi FUCHIKAMI, Naoko TAKEDA, Nana NATSUME, Masahiro KATO
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2023; 84(2): 238. CrossRef
Identification of key breast features using a neural network: applications of machine learning in the clinical setting of Plastic Surgery
Nitzan Kenig, Javier Monton Echeverria, Luis De la Ossa
Plastic & Reconstructive Surgery.2023;[Epub] CrossRef
Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy
A. T. P. M. Brands-Appeldoorn, A. J. G. Maaskant-Braat, L. Janssen, L. A. D. M. van Osch, V. C. G. Tjan-Heijnen, R. M. H. Roumen
Breast Cancer.2022; 29(1): 114. CrossRef
BROWSE: A multicentre comparison of nine year outcomes in acellular dermal matrix based and complete submuscular implant-based immediate breast reconstruction-aesthetics, capsular contracture and patient reported outcomes
Rebecca L. Wilson, Cliona C. Kirwan, Joe M. O'Donoghue, Richard A. Linforth, Richard K. Johnson, James R. Harvey
European Journal of Surgical Oncology.2022; 48(1): 73. CrossRef
Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer
A. T. P. M. Brands-Appeldoorn, R. C. M. Thomma, L. Janssen, A. J. G. Maaskant-Braat, V. C. G. Tjan-Heijnen, R. M. H. Roumen
Breast Cancer Research and Treatment.2022; 191(3): 545. CrossRef
Adaptation of BCCT Learning Model in Developing Religious Aspects of Children
Abd Hamid Wahid, Muhammad Fajri, Hasan Baharun, Riana Imroatul Fitriyah, Arifatur Risqiyah
Jurnal Obsesi : Jurnal Pendidikan Anak Usia Dini.2022; 6(4): 3439. CrossRef
Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients’ and Physicians’ Assessment from the Randomized IMRT-MC2 Trial
Tobias Forster, Clara Köhler, Melissa Dorn, Matthias Felix Häfner, Nathalie Arians, Laila König, Semi Ben Harrabi, Ingmar Schlampp, Eva Meixner, Vanessa Heinrich, Nicola Weidner, Michael Golatta, André Hennigs, Jörg Heil, Holger Hof, David Krug, Jürgen De
Cancers.2022; 14(12): 3010. CrossRef
Feasibility of anomaly score detected with deep learning in irradiated breast cancer patients with reconstruction
Dong-Yun Kim, Soo Jin Lee, Eun-Kyu Kim, Eunyoung Kang, Chan Yeong Heo, Jae Hoon Jeong, Yujin Myung, In Ah Kim, Bum-Sup Jang
npj Digital Medicine.2022;[Epub] CrossRef
Breast Oncoplastic Resections: No Innovation Without Evaluation
Sherif Monib, Mohamed Farag, Mohamed Ibrahim
Indian Journal of Surgery.2021; 83(S2): 409. CrossRef
Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer
Asal Rahimi, Howard E. Morgan, Dong W. Kim, Yuanyuan Zhang, Marilyn Leitch, Rachel Wooldridge, Sally Goudreau, Barbara Haley, Roshni Rao, Aeisha Rivers, Ann E. Spangler, Ryan T. Jones, Stella Stevenson, Jason Staley, Kevin Albuquerque, Chul Ahn, Sarah Neu
International Journal of Radiation Oncology*Biology*Physics.2021; 110(3): 772. CrossRef
Comparative study between laparoscopically harvested omental flap and glandular flap in immediate reconstruction after conservative surgery in breast cancer
Waleed Y. El‐Sherpiny, Abdulhamid M. Abdelshafi, Mohamed Ghazaly, Ayman A. Elnemr, Ahmed A. Darwish, Mohamed A. Mlees
Surgical Practice.2021; 25(2): 92. CrossRef
Reliability of the BCCT.core software in evaluation of breast cosmesis – A systematic review
Stami Trakis, Heidi Lord, Peter Graham, Ritin Fernandez
Journal of Medical Imaging and Radiation Oncology.2021; 65(6): 817. CrossRef
New criteria for breast symmetry evaluation after breast conserving surgery for cancer
RENÉ ALOISIO DA COSTA VIEIRA, GABRIELE BILLER, FABIOLA CRISTINA BRANDINI DA SILVA, JONATHAS JOSÉ DA SILVA, MARCO ANTÔNIO DE OLIVEIRA, ANTÔNIO BAILÃO-JUNIOR
Revista do Colégio Brasileiro de Cirurgiões.2021;[Epub] CrossRef
Use of Symmetry Assessment Methods in the Context of Breast Surgery
Javier Monton, Asia Torres, Maria Gijon, Luis Chang-Azancot, Nitzan Kenig, P. Camelia Trandafir, Joaquin Jordan, Ricardo Insausti
Aesthetic Plastic Surgery.2020; 44(5): 1440. CrossRef
Visual Breast Asymmetry Assessment with Optical-Flow Algorithm
Javier Monton, Nitzan Kenig, Ricardo Insausti, Joaquin Jordan
Journal of Medical Systems.2020;[Epub] CrossRef
Nueva metodología para medir simetría frontal en pacientes reconstruidas por cáncer de mama
Lenia Sánchez Wals, Carlos Acosta-Batista, Oscar Luis Vera Pérez, Juan Jesús Lence Anta, Marco Marcasciano
Revista de Senología y Patología Mamaria.2019; 32(4): 133. CrossRef
Objective assessment of flap volume changes and aesthetic results after adjuvant radiation therapy in patients undergoing immediate autologous breast reconstruction
Yujin Myung, Yousung Son, Tae-hyun Nam, Eunyoung Kang, Eun-Kyu Kim, In Ah Kim, Keun-Yong Eom, Chan Yeong Heo, Jae Hoon Jeong, Fabio Santanelli, di Pompeo d'Illasi
PLOS ONE.2018; 13(5): e0197615. CrossRef

21,519 View
122 Download
21 Web of Science
22 Crossref

The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo: Keun-Yong Eom, Bong Jun Cho, Eun Jung Choi, Jin-Ho Kim, Eui Kyu Chie, Hong-Gyun Wu, Il Han Kim, Sun Ha Paek, Jae-Sung Kim, In Ah Kim; Cancer Res Treat. 2016;48(2):687-697. Published online June 4, 2015; DOI: https://doi.org/10.4143/crt.2014.320

Abstract PDF PubReader ePub

Purpose
We investigated the effect of chemoradiotherapy with PP2 and temozolomide (TMZ) on malignant glioma cells using clonogenic assays and in vivo brain tumor model.
Materials and Methods
The effect of PP2 on radiosensitivity of U251 and T98G cells was investigated using clonogenic assays. The expression of E-cadherin, matrix metalloproteinases 2 (MMP2), Ephrin type-A receptor 2 (EphA2), and vascular endothelial growth factor (VEGF) was measured by Western blotting and an accumulation of γH2AX foci 6 hours after radiotherapy was measured after PP2 treatment. The effect of PP2 on migration, invasion, and vasculogenic mimicry formation (VMF) of U251 cells was evaluated. In an orthotopical brain tumor model with U251 cells, PP2 was injected intraperitoneally with or without oral TMZ before, during and after whole brain radiotherapy. Bioluminescence images were taken to visualize in vivo tumors and immunohistochemical staining of VEGF, CD31, EphA2, and hypoxia-inducible factor 1a was performed.
Results
PP2 increased radiosensitivity of U251 and T98G cells without decreasing survival of normal human astrocytes. Chemoradiotherapy with PP2 and TMZ resulted in increased accumulation of γH2AX foci. PP2 induced overexpression of E-cadherin and suppression of MMP2, VEGF, and EphA2. PP2 also compromised invasion, migration, and VMF of U251 cells. In brain tumors, chemoradiotherapy with PP2 and TMZ decreased tumor volume best, but not statistically significantly compared with chemoradiotherapy with TMZ. The expression of VEGF and CD31 was suppressed in PP2-treated tumors.
Conclusion
PP2 enhances radiosensitivity of malignant glioma cells and suppresses invasion and migration of U251 cells. Chemoradiotherapy with PP2 and TMZ resulted in non-significant tumor volume decrease.

Citations

Citations to this article as recorded by

Dihydroartemisinin inhibits EphA2/PI3K/Akt pathway-mediated malignant behaviors and vasculogenic mimicry in glioma stem cells
Huangde Fu, Shengtian Wu, Hechun Shen, Kai Luo, Zhongxiang Huang, Nankun Lu, Yaolin Li, Qian Lan, Yishun Xian
Heliyon.2025; 11(3): e42095. CrossRef
c-Src inhibitor PP2 inhibits head and neck cancer progression through regulation of the epithelial–mesenchymal transition
SunYoung Lee, Sunjung Park, Jae-Sung Ryu, Jaegu Kang, Ikhee Kim, Sumin Son, Bok-Soon Lee, Chul-Ho Kim, Yeon Soo Kim
Experimental Biology and Medicine.2023; 248(6): 492. CrossRef
Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings
Emir Begagić, Ragib Pugonja, Hakija Bečulić, Amila Čeliković, Lejla Tandir Lihić, Samra Kadić Vukas, Lejla Čejvan, Rasim Skomorac, Edin Selimović, Belma Jaganjac, Fatima Juković-Bihorac, Aldin Jusić, Mirza Pojskić
Brain Sciences.2023; 13(11): 1602. CrossRef
Hemorrhage in brain tumor – An unresolved issue
Robert P. Ostrowski, Zhaohui He, Emanuela B. Pucko, Ewa Matyja
Brain Hemorrhages.2022; 3(2): 98. CrossRef
The interactions of CAP and LYN with the insulin signaling transducer CBL play an important role in polycystic ovary syndrome
Haoran Shen, Xiao Xu, Zhongpeng Fu, Chengjie Xu, Yao Wang
Metabolism.2022; 131: 155164. CrossRef
Identification of four key prognostic genes and three potential drugs in human papillomavirus negative head and neck squamous cell carcinoma
Guocai Tian, You Fu, Dahe Zhang, Jiang Li, Zhiyuan Zhang, Xi Yang
Cancer Cell International.2021;[Epub] CrossRef
Intracellular Progesterone Receptor and cSrc Protein Working Together to Regulate the Activity of Proteins Involved in Migration and Invasion of Human Glioblastoma Cells
Claudia Bello-Alvarez, Aylin Del Moral-Morales, Aliesha González-Arenas, Ignacio Camacho-Arroyo
Frontiers in Endocrinology.2021;[Epub] CrossRef
Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1
Hoon Sik Choi, Jin Hyun Kim, Si Jung Jang, Jeong Won Yun, Ki Mun Kang, Hojin Jeong, In Bong Ha, Bae Kwon Jeong
Cancer Research and Treatment.2021; 53(3): 685. CrossRef
Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications
Raúl Ortiz, Gloria Perazzoli, Laura Cabeza, Cristina Jiménez-Luna, Raquel Luque, Jose Prados, Consolación Melguizo
Current Neuropharmacology.2021; 19(4): 513. CrossRef
SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines
Filippo Torrisi, Luigi Minafra, Francesco P. Cammarata, Gaetano Savoca, Marco Calvaruso, Nunzio Vicario, Laura Maccari, Elodie A. Pérès, Hayriye Özçelik, Myriam Bernaudin, Lorenzo Botta, Giorgio Russo, Rosalba Parenti, Samuel Valable
International Journal of Molecular Sciences.2020; 21(11): 3917. CrossRef
SRC Kinase in Glioblastoma: News from an Old Acquaintance
Claudia Cirotti, Claudia Contadini, Daniela Barilà
Cancers.2020; 12(6): 1558. CrossRef
Development of a patient-derived xenograft model of glioblastoma via intravitreal injection in mice
Jooyoung Lee, Dong Hyun Jo, Jin Hyoung Kim, Chang Sik Cho, Jiwon Esther Han, Yona Kim, Hyoungwoo Park, Seung Ho Yoo, Young Suk Yu, Hyo Eun Moon, Hye Ran Park, Dong Gyu Kim, Jeong Hun Kim, Sun Ha Paek
Experimental & Molecular Medicine.2019; 51(4): 1. CrossRef
Antagonism between the RNA-binding protein Musashi1 and miR-137 and its potential impact on neurogenesis and glioblastoma development
Mitzli X. Velasco, Adam Kosti, Gabriela D.A. Guardia, Marcia C. Santos, Allison Tegge, Mei Qiao, Bruna R.S. Correa, Greco Hernández, Erzsebet Kokovay, Pedro A.F. Galante, Luiz O.F. Penalva
RNA.2019; 25(7): 768. CrossRef
Suppression of the Smurf1 Expression Inhibits Tumor Progression in Gliomas
Hao Chang, Jingning Zhang, Zengli Miao, Yasuo Ding, Xing Xu, Xudong Zhao, Peng Xu, Qing Wang, Yuchang Lin
Cellular and Molecular Neurobiology.2018; 38(2): 421. CrossRef
ZEB1‐mediated vasculogenic mimicry formation associates with epithelial–mesenchymal transition and cancer stem cell phenotypes in prostate cancer
Hua Wang, Bin Huang, Bai Mou Li, Kai Yuan Cao, Chen Qiang Mo, Shuang Jian Jiang, Jin Cheng Pan, Zong Ren Wang, Huan Yi Lin, Dao Hu Wang, Shao Peng Qiu
Journal of Cellular and Molecular Medicine.2018; 22(8): 3768. CrossRef
CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair
Yuzhen Zhou, Li Chu, Qi Wang, Weixing Dai, Xiaozhou Zhang, Jianfeng Chen, Ling Li, Peipei Ding, Long Zhang, Hongyu Gu, Luying Li, Xinyue Lv, Wei Zhang, Danlei Zhou, Pingzhao Zhang, Guoxiang Cai, Kuaile Zhao, Weiguo Hu
Cell Death & Disease.2018;[Epub] CrossRef
KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma
Michael J. Ciesielski, Yahao Bu, Stephan A. Munich, Paola Teegarden, Michael P. Smolinski, James L. Clements, Johnson Y. N. Lau, David G. Hangauer, Robert A. Fenstermaker
Journal of Neuro-Oncology.2018; 140(3): 519. CrossRef
The function and mechanism of preactivated thiomers in triggering epithelial tight junctions opening
Yang Zhang, Shurong Zhou, Feiyang Deng, Xianhui Chen, Xing Wang, Yaoqi Wang, Hua Zhang, Wenbing Dai, Bing He, Qiang Zhang, Xueqing Wang
European Journal of Pharmaceutics and Biopharmaceutics.2018; 133: 188. CrossRef
The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
Fei Shi, Jinying Zhang, Hongyu Liu, Liangliang Wu, Hongyu Jiang, Qiyan Wu, Tianyi Liu, Meiqing Lou, Hao Wu
Oncotarget.2018; 9(1): 706. CrossRef
Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP
Sung-Won Shin, Changhoon Choi, Ga-Haeng Lee, Arang Son, Su-Hyeon Kim, Hee Chul Park, Ines Batinic-Haberle, Won Park
Antioxidants & Redox Signaling.2017; 27(14): 1067. CrossRef
Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression
Lei Chen, Damin Cong, Yongzhe Li, Dan Wang, Qingsong Li, Shaoshan Hu
Ultrasonics Sonochemistry.2017;[Epub] CrossRef
Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells
Tosol Yu, Bong Jun Cho, Eun Jung Choi, Ji Min Park, Dan Hyo Kim, In Ah Kim
Oncotarget.2016; 7(48): 79089. CrossRef
RND3 promotes Snail 1 protein degradation and inhibits glioblastoma cell migration and invasion
Baohui Liu, Huimin Dong, Xi Lin, Xiangsheng Yang, Xiaojing Yue, Jian Yang, Yuntao Li, Liquan Wu, Xiaonan Zhu, Shenqi Zhang, Daofeng Tian, Junmin Wang, Qiang Cai, Shanping Mao, Qianxue Chen, Jiang Chang
Oncotarget.2016; 7(50): 82411. CrossRef

13,581 View
170 Download
25 Web of Science
23 Crossref

The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer: Keun-Yong Eom, Min Hye Jang, So Yeon Park, Eun Young Kang, Sung Won Kim, Jee Hyun Kim, Jae-Sung Kim, In Ah Kim; Cancer Res Treat. 2016;48(1):125-132. Published online March 3, 2015; DOI: https://doi.org/10.4143/crt.2014.243

Abstract PDF PubReader ePub

Purpose
The aim of study was to test by immunohistochemical (IHC) staining whether carbonic anhydrase (CA) 9 and 12 have an effect on sentinel lymph node (SLN) metastasis in early breast cancer and to find clinicopathologic factors associated with SLN metastasis.
Materials and Methods
Between June 2003 and June 2011, medical records of 470 patients diagnosedwith breast cancer with pT1-2, pN0-2, and M0 were reviewed. Of these 470, 314 patients who underwent SLN biopsy±axillary dissection were subjects of this study. Using tissue microarray, IHC staining for CA9 and CA12 was performed. Clinicopathologic factors such as patient age, tumour size, lymphatic invasion, hormone receptor status, and the Ki-67 labeling index were analysed together.
Results
The mean age of all patients was 51.7 years. The mean number of harvested SLN was 3.62, and 212 patients (67.5%) had negative SLN. Lymphatic invasion, the Ki-67 labelling index of primary tumours, and CA9 staining of stromal cells, were independent risk factors for SLN metastasis in the multivariate analysis. In 33 patients (10.5%) without the three risk factors, no patient had SLN metastasis. In 80 patients without lymphatic invasion of primary tumours or CA9 staining of stromal cells, only four patients (5%) had positive SLN.
Conclusion
CA9 staining of stromal cells is an independent risk factor for SLN metastasis as well as lymphatic invasion and a low Ki-67 labelling index of primary tumours in patients with early breast cancer. IHC staining of primary tumours for CA12was not associatedwith SLN metastasis.

Citations

Citations to this article as recorded by

Impact of CA9 expression in the diagnosis of lymph-node metastases in non-small cell lung cancer based on [18F]FDG PET/CT
Satoshi Suzuki, Masakazu Yashiro, Nobuhiro Izumi, Takuma Tsukioka, Hidetoshi Inoue, Kantaro Hara, Ryuichi Ito, Takuya Tanimura, Noritoshi Nishiyama, Domenico Albano
PLOS ONE.2024; 19(10): e0312846. CrossRef
Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling
Daniele Vergara, Sara Ravaioli, Eugenio Fonzi, Loredaria Adamo, Marina Damato, Sara Bravaccini, Francesca Pirini, Antonio Gaballo, Raffaela Barbano, Barbara Pasculli, Julien Franck, Isabelle Fournier, Michel Salzet, Michele Maffia
International Journal of Molecular Sciences.2020; 21(3): 715. CrossRef
The Interplay of Dysregulated pH and Electrolyte Imbalance in Cancer
Khalid O. Alfarouk, Samrein B. M. Ahmed, Ahmed Ahmed, Robert L. Elliott, Muntaser E. Ibrahim, Heyam S. Ali, Christian C. Wales, Ibrahim Nourwali, Ahmed N. Aljarbou, Adil H. H. Bashir, Sari T. S. Alhoufie, Saad Saeed Alqahtani, Rosa A. Cardone, Stefano Fai
Cancers.2020; 12(4): 898. CrossRef
Identification and validation of a combined hypoxia and immune index for triple‐negative breast cancer
Shaoquan Zheng, Yutian Zou, Jie‐ying Liang, Weikai Xiao, Anli Yang, Tiebao Meng, Shilin Lu, Zhongbing Luo, Xiaoming Xie
Molecular Oncology.2020; 14(11): 2814. CrossRef
The roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis
Simonas Daunys, Vilma Petrikaitė
Biology of the Cell.2020; 112(12): 383. CrossRef
Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer
Min-Sun Jin, Hyebin Lee, In Ae Park, Yul Ri Chung, Seock-Ah Im, Kyung-Hun Lee, Hyeong-Gon Moon, Wonshik Han, Kyubo Kim, Tae-Yong Kim, Dong-Young Noh, Han Suk Ryu
Virchows Archiv.2016; 469(2): 183. CrossRef
Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker
Bo Lei, Xian-yu Zhang, Jia-peng Zhou, Guan-nan Mu, Yi-wen Li, You-xue Zhang, Da Pang
Tumor Biology.2016; 37(11): 14757. CrossRef
Three-Dimensional Breast Cancer Models Mimic Hallmarks of Size-Induced Tumor Progression
Manjulata Singh, Shilpaa Mukundan, Maria Jaramillo, Steffi Oesterreich, Shilpa Sant
Cancer Research.2016; 76(13): 3732. CrossRef

14,187 View
121 Download
10 Web of Science
8 Crossref

In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation: Eui Kyu Chie, Jin Hee Shin, Jin Ho Kim, Hak Jae Kim, In Ah Kim, Il Han Kim; Cancer Res Treat. 2015;47(3):527-533. Published online November 24, 2014; DOI: https://doi.org/10.4143/crt.2014.026

Abstract PDF PubReader ePub

Purpose
This study was conducted in order to validate the radiosensitization effect of valproic acid, a biologically available histone deacetylase inhibitor, for fractionated radiation.
Materials and Methods
Radiosensitization effect of valproic acid was tested for the A549 cell line and U87MG cell line in vitro. Fractionated irradiation of 12 Gy in four fractions was administered on D2-5 with valproic acid, 150 mg/Kg, ip, bid for six consecutive days (D1-6) to A549 and U87MG tumors implanted in BALB/c-nude mice. A growth delay curve was formulated.
Results
Radiosensitization effect of valproic acid was found for both cell lines; A549 at 1.5 mM and 3.0 mM concentration and U87MG at 3.0 mM concentration. In growth delay analysis, a statistically significant radiosensitization effect was observed for both tumors (p < 0.001 for both tumors). Difference for change in slope for control and valproic acid versus radiotherapy and radiotherapy plus valproic acid showed borderline significance for the U87MG cell line (p=0.065), indicating beyond additive effect, whereas this difference was statistically insignificant for A549 tumor (p=0.951), indicating additive effect.
Conclusion

Results
of this study indicate that a radiosensitizing effect for fractionated radiotherapy of valproic acid for A549 and U87MG tumors in vivo is evident and that it may be more than additive for U87MG tumors. Further exploitation of histone deacetylase inhibitors in clinical trials is warranted.

Citations

Citations to this article as recorded by

Anti-epileptic drug use during adjuvant chemo-radiotherapy is associated with poorer survival in patients with glioblastoma: A nationwide population-based cohort study
Peng-Yi Lee, Yu-Ting Wei, Kun-San Clifford Chao, Chin-Nan Chu, Wen-Hui Chung, Ti-Hao Wang*
Journal of Cancer Research and Therapeutics.2024; 20(2): 555. CrossRef
Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis
Jessica K Sullivan, Paul P Fahey, Kinglsey E Agho, Simon P Hurley, Zhihui Feng, Richard O Day, David Lim
Neuro-Oncology Practice.2023; 10(1): 13. CrossRef
The function of histone methylation and acetylation regulators in GBM pathophysiology
Colin McCornack, Timothy Woodiwiss, Angela Hardi, Hiroko Yano, Albert H. Kim
Frontiers in Oncology.2023;[Epub] CrossRef
Antitumor Activity of Non-thermal Atmospheric Pressure Plasma and Synergistic Effects of Hyperthermia
TETSUO ADACHI
Thermal Medicine.2022; 38(1): 1. CrossRef
Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy
Joerg Kotzerke, Dorothee Buesser, Anne Naumann, Roswitha Runge, Lisa Huebinger, Andrea Kliewer, Robert Freudenberg, Claudia Brogsitter
Cancers.2022; 14(10): 2513. CrossRef
Molecular Mechanisms Underlying Cellular Responses to the Loading of Non-thermal Atmospheric Pressure Plasma-activated Solutions
Tetsuo Adachi
YAKUGAKU ZASSHI.2021; 141(10): 1185. CrossRef
Ability of plasma-activated acetated Ringer’s solution to induce A549 cell injury is enhanced by a pre-treatment with histone deacetylase inhibitors
Tetsuo Adachi, Yumiko Matsuda, Rika Ishii, Tetsuro Kamiya, Hirokazu Hara
Journal of Clinical Biochemistry and Nutrition.2020; 67(3): 232. CrossRef
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide
Yu-Jen Kuo, Yao-Hsu Yang, I-Yun Lee, Pau-Chung Chen, Jen-Tsung Yang, Ting-Chung Wang, Martin Hsiu-Chu Lin, Wei-Hsun Yang, Chun-Yu Cheng, Kuo-Tai Chen, Wei-Chao Huang, Ming-Hsueh Lee
Medicine.2020; 99(28): e21147. CrossRef
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
Rashmi R. Shah, Peter D. Stonier
Journal of Clinical Pharmacy and Therapeutics.2019; 44(1): 6. CrossRef
Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation
Jeong Il Yu, Changhoon Choi, Sung-Won Shin, Arang Son, Ga-Haeng Lee, Shin-Yeong Kim, Hee Chul Park
Scientific Reports.2017;[Epub] CrossRef
Histone deacetylase inhibitors stimulate the susceptibility of A549 cells to a plasma-activated medium treatment
Tetsuo Adachi, Ayame Kano, Saho Nonomura, Tetsuro Kamiya, Hirokazu Hara
Archives of Biochemistry and Biophysics.2016; 606: 120. CrossRef
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
Caroline Happold, Thierry Gorlia, Olivier Chinot, Mark R. Gilbert, L. Burt Nabors, Wolfgang Wick, Stephanie L. Pugh, Monika Hegi, Timothy Cloughesy, Patrick Roth, David A. Reardon, James R. Perry, Minesh P. Mehta, Roger Stupp, Michael Weller
Journal of Clinical Oncology.2016; 34(7): 731. CrossRef

11,637 View
107 Download
15 Web of Science
12 Crossref

Sequence-Dependent Radiosensitization of Histone Deacetylase Inhibitors Trichostatin A and SK-7041: Jin Ho Kim, Il Han Kim, Jin Hee Shin, Hak Jae Kim, In Ah Kim; Cancer Res Treat. 2013;45(4):334-342. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.334

Abstract PDF PubReader ePub

PURPOSE
This preclinical study is to determine whether the capacity of histone deacetylase (HDAC) inhibitors to enhance radiation response depends on temporal sequences of HDAC inhibition and irradiation.
MATERIALS AND METHODS
The effects of HDAC inhibitors trichostatin A (TSA) and SK-7041 on radiosensitivity in human lung cancer cells were examined using a clonogenic assay, exposing cells to HDAC inhibitors in various sequences of HDAC inhibition and radiation. We performed Western blot of acetylated histone H3 and flow cytometry to analyze cell cycle phase distribution.
RESULTS
TSA and SK-7041 augmented radiation cell lethality in an exposure time-dependent manner when delivered before irradiation. The impact of TSA and SK-7041 on radiosensitivity rapidly diminished when HDAC inhibition was delayed after irradiation. Radiation induced the acetylation of histone H3 in cells exposed to TSA, while irradiation alone had no effect on the expression of acetylated histone H3 in TSA-naive cells. Preirradiation exposure to TSA abrogated radiation-induced G2/M-phase arrest. When delivered after irradiation, TSA had no effect on the peak of radiation-induced G2/M-phase arrest.
CONCLUSION
TSA and SK-7041 enhances radiosensitivity only when delivered before irradiation. Unless proven otherwise, it seems prudent to apply scheduling including preirradiation HDAC inhibition so that maximal radiosensitization is obtained.

Citations

Citations to this article as recorded by

Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview
Elsie Neo Seane, Shankari Nair, Charlot Vandevoorde, Anna Joubert
Pharmaceuticals.2024; 17(5): 602. CrossRef
Investigation of geroprotective and radioprotective effects of berberine and trichostatin A on the model of Drosophila melanogaster
N. Ulyasheva, E. Proshkina, M. Shaposhnikov, A. Moskalev
Proceedings of the Komi Science Centre of the Ural Division of the Russian Academy of Sciences.2023; 0(6): 93. CrossRef
Low Dose of Trichostatin A Improves Radiation Resistance by Activating Akt/Nrf2-Dependent Antioxidation Pathway in Cancer Cells
Fengqiu Zhang, Changsheng Shao, Zhu Chen, Yalin Li, Xumiao Jing, Qing Huang
Radiation Research.2021;[Epub] CrossRef
Time-sequential change in immune-related gene expression after irradiation in glioblastoma: next-generation sequencing analysis
Yi-Jun Kim, Kwangsoo Kim, Soo Yeon Seo, Juyeon Yu, Il Han Kim, Hak Jae Kim, Chul-Kee Park, Kye Hwa Lee, Junjeong Choi, Myung Seon Song, Jin Ho Kim
Animal Cells and Systems.2021; 25(4): 245. CrossRef
Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
Fengqiu Zhang, Zhu Chen, Changsheng Shao, Qing Huang
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.2019; 813: 13. CrossRef
Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim
Cancer Research and Treatment.2019; 51(2): 696. CrossRef
Psammaplin A-Modified Novel Radiosensitizers for Human Lung Cancer and Glioblastoma Cells
Chan Woo Wee, Jin Ho Kim, Hak Jae Kim, Hyun-Cheol Kang, Soo Youn Suh, Beom Soo Shin, Eunsook Ma, Il Han Kim
Journal of Radiation Protection and Research.2019; 44(1): 15. CrossRef
Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization
Jin Ho Kim, Sung Ho Moon, Mina No, Jae Jin Kim, Eun Jung Choi, Bong Jun Cho, Jae Sung Kim, Il Han Kim, In Ah Kim
Cancer Research and Treatment.2016; 48(3): 1130. CrossRef

12,611 View
47 Download
6 Web of Science
8 Crossref

Enhancement of Radiation Effects by Flavopiridol in Uterine Cervix Cancer Cells: Suzy Kim, Hong-Gyun Wu, Jin Hee Shin, Hye Jin Park, In Ah Kim, Il Han Kim; Cancer Res Treat. 2005;37(3):191-195. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.191

Abstract PDF PubReader ePub

Purpose

To determine the effects of combinations of radiation and flavopiridol, an inhibitor of cyclin-dependent kinases and global transcription, in a human uterine cervix cancer cell line.

Materials and Methods

Human uterine cervix cancer cells (HeLa), cultured to the mid-log phase, were exposed to X-rays, flavopiridol, and combinations of X-rays and flavopiridol in various sequences. The end point in this study was the clonogenic survival, which was measured via clonogenic assays. In order to determine the intrinsic cytotoxicity of flavopiridol, 0, 5, 12.5, 25, 37.5, 50 and 100 nM of flavopiridol were added to cell culture media. In the combination treatment, four different schedules of flavopiridol and irradiation combinations were tested: treatment of flavopiridol for 24 hours followed by irradiation, simultaneous administration of flavopiridol and irradiation, and irradiation followed by flavopiridol (for 24 hours) at intervals of 6 and 24 hours. The fraction of cells surviving after the combination treatment with 2 Gy of radiation (SF2) was compared with that of the fraction of cells surviving after treatment with irradiation alone.

Results

The cytotoxicity of flavopiridol was found to be dose-dependent, with an IC50 of 80 nM. No cytotoxic enhancements were observed when flavopiridol and radiation were administered simultaneously. Flavopiridol, administered either 24 hours before or 6 hours after irradiation, exerted no sensitizing effects on the cells. Only one protocol resulted in a radiosensitizing effect: the administration of flavopiridol 24 hours after irradiation.

Conclusion

Flavopiridol enhanced the effects of radiation on a uterine cervix cancer cell line in vitro, and this enhancement was both sequence- and time-dependent.

Citations

Citations to this article as recorded by

Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment
Uttam Singh Baghel, Priyanka Kriplani, Neelam M. Patel, Manpreet Kaur, Kapil Sharma, Monika Meghani, Abhay Sharma, Deeksha Singh, Bhawani Singh, William N. Setzer, Javad Sharifi-Rad, Daniela Calina
Naunyn-Schmiedeberg's Archives of Pharmacology.2024;[Epub] CrossRef
BAIRDA: a novel in vitro setup to quantify radiobiological parameters for cervical cancer brachytherapy dose estimations
Braden Chow, Brad Warkentin, Kareena Nanda, Sunita Ghosh, Fleur Huang, Armin M Gamper, Geetha Menon
Physics in Medicine & Biology.2022; 67(4): 045012. CrossRef
Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy
Marco Calvaruso, Gaia Pucci, Rosa Musso, Valentina Bravatà, Francesco P. Cammarata, Giorgio Russo, Giusi I. Forte, Luigi Minafra
International Journal of Molecular Sciences.2019; 20(21): 5267. CrossRef
Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor
Young Eun Lee, Seung Ah Choi, Pil Ae Kwack, Hak Jae Kim, Il Han Kim, Kyu-Chang Wang, Ji Hoon Phi, Ji Yeoun Lee, Sangjoon Chong, Sung-Hye Park, Kyung Duk Park, Do Won Hwang, Kyeung Min Joo, Seung-Ki Kim
Neuro-Oncology.2017; 19(8): 1079. CrossRef
Interaction of ω-3 polyunsaturated fatty acids with radiation therapy in two different colorectal cancer cell lines
Fang Cai, Olivier Sorg, Virginie Granci, Elena Lecumberri, Raymond Miralbell, Yves M. Dupertuis, Claude Pichard
Clinical Nutrition.2014; 33(1): 164. CrossRef
Antitumor Effects of Flavopiridol on Human Uterine Leiomyoma In Vitro and in a Xenograft Model
Hyun-Gyo Lee, Jong-Woo Baek, So-Jin Shin, Sang-Hoon Kwon, Soon-Do Cha, Won-Jin Park, Rosa Chung, Eun-Som Choi, Gun-Ho Lee, Chi-Heum Cho
Reproductive Sciences.2014; 21(9): 1153. CrossRef
In VitroRadiosensitization of Flavopiridol Did Not Translated intoIn VivoRadiosensitization
Suzy Kim
The Journal of the Korean Society for Therapeutic Radiology and Oncology.2011; 29(2): 83. CrossRef
Gold Nanoparticles as Radiation Sensitizers in Cancer Therapy
Devika B. Chithrani, Salomeh Jelveh, Farid Jalali, Monique van Prooijen, Christine Allen, Robert G. Bristow, Richard P. Hill, David A. Jaffray
Radiation Research.2010; 173(6): 719. CrossRef

9,289 View
51 Download
8 Crossref

A Histone Deacetylase Inhibitor, Trichostatin A, Enhances Radiosensitivity by Abrogating G2/M Arrest in Human Carcinoma Cells: In Ah Kim, Jin Ho Kim, Jin Hee Shin, Il Han Kim, Jae Sung Kim, Hong-Gyun Wu, Eui Kyu Chie, Yong Ho Kim, Bo-Kyung Kim, Semie Hong, Seok Won Park, Sung Whan Ha, Charn Il Park; Cancer Res Treat. 2005;37(2):122-128. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.122

Abstract PDF PubReader ePub

Purpose

Histone deacetylase inhibitors (HDIs) are emerging as potentially useful components in anticancer therapy. In this study, we tried to confirm the radiosensitizing effect of trichostatin A (TSA) on a panel of human carcinoma cell lines and elucidate its mechanism of interaction.

Materials and Methods

A549, HeLa and Caski cells were exposed to TSA for 18 hr prior to irradiation, and the cell survival then measured using a clonogenic assay. Western blot and flow cytometric analyses, for histone acetylation, and cell cycle and apoptosis, respectively, were also performed.

Results

TSA increased the acetylation of histone H3. The pretreatment of TSA consistently radiosensitized all three cell lines. The SF2 (surviving fraction at 2 Gy) of TSA-treated cells was significantly lower than that of mock treated cells. The SER (sensitizer enhancement ratio) increased in all 3 cell lines, in concentration dependent manners. The TSA treated cells showed abrogation of radiation-induced G2/M arrest, in a concentration dependent manner.

Conclusion

The pretreatment of TSA enhanced the radiosensitivity of a panel of human carcinoma cells, which was attributed, in part, to the abrogation of radiation-induced G2/M arrest.

Citations

Citations to this article as recorded by

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Yijun Xie, Di Xiao, Duo Li, Mei Peng, Wei Peng, Huaxin Duan, Xiaoping Yang
Frontiers in Oncology.2024;[Epub] CrossRef
Radiosensitizing effect of dendrosomal nanoformulation of curcumin on cancer cells
Tahereh Jalali Varnamkhasti, Meisam Jafarzadeh, Majid Sadeghizadeh, Mahdi Aghili
Pharmacological Reports.2022; 74(4): 718. CrossRef
Pharmacological Properties of Trichostatin A, Focusing on the Anticancer Potential: A Comprehensive Review
Abdelhakim Bouyahya, Nasreddine El Omari, Mohamed Bakha, Tarik Aanniz, Naoual El Menyiy, Naoufal El Hachlafi, Aicha El Baaboua, Mohamed El-Shazly, Mohammed Merae Alshahrani, Ahmed Abdullah Al Awadh, Learn-Han Lee, Taoufiq Benali, Mohammad S. Mubarak
Pharmaceuticals.2022; 15(10): 1235. CrossRef
Low Dose of Trichostatin A Improves Radiation Resistance by Activating Akt/Nrf2-Dependent Antioxidation Pathway in Cancer Cells
Fengqiu Zhang, Changsheng Shao, Zhu Chen, Yalin Li, Xumiao Jing, Qing Huang
Radiation Research.2021;[Epub] CrossRef
Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
Frontiers in Oncology.2021;[Epub] CrossRef
Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
Fengqiu Zhang, Zhu Chen, Changsheng Shao, Qing Huang
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.2019; 813: 13. CrossRef
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
Manuela Terranova-Barberio, Biagio Pecori, Maria Serena Roca, Serena Imbimbo, Francesca Bruzzese, Alessandra Leone, Paolo Muto, Paolo Delrio, Antonio Avallone, Alfredo Budillon, Elena Di Gennaro
Journal of Experimental & Clinical Cancer Research.2017;[Epub] CrossRef
Histone Acetylation Induced Transformation of B-DNA to Z-DNA in Cells Probed through FT-IR Spectroscopy
Fengqiu Zhang, Qing Huang, Jingwen Yan, Zhu Chen
Analytical Chemistry.2016; 88(8): 4179. CrossRef
Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors
Vincent Zwick, Claudia Simões-Pires, Muriel Cuendet
Journal of Enzyme Inhibition and Medicinal Chemistry.2016; 31(sup1): 209. CrossRef
Assessment of the Effect of Trichostatin A on HeLa Cells through FT-IR Spectroscopy
Fengqiu Zhang, Qing Huang, Jingwen Yan, Xin Zhang, Jianxin Li
Analytical Chemistry.2015; 87(4): 2511. CrossRef
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
Ahrum Min, Seock-Ah Im, Debora Keunyoung Kim, Sang-Hyun Song, Hee-Jun Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J O’Connor, Yung-Jue Bang
Breast Cancer Research.2015;[Epub] CrossRef
CD44 is a biomarker associated with human prostate cancer radiation sensitivity
WeiWei Xiao, Peter H. Graham, Carl A. Power, Jingli Hao, John H. Kearsley, Yong Li
Clinical & Experimental Metastasis.2012; 29(1): 1. CrossRef
Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
Han Sang Kim, Sang Cheol Kim, Sun Jeong Kim, Chan Hee Park, Hei-Cheul Jeung, Yong Bae Kim, Joong Bae Ahn, Hyun Cheol Chung, Sun Young Rha
BMC Genomics.2012;[Epub] CrossRef
In vivoRadiosensitization Effect of HDAC Inhibitor, SK-7041 on RIF-1 Cell Line
Eui Kyu Chie, Jin Hee Shin, In Ah Kim, Il Han Kim
The Journal of the Korean Society for Therapeutic Radiology and Oncology.2010; 28(4): 219. CrossRef
Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6
In Ah Kim, Mina No, Jang Mi Lee, Jin Hee Shin, Jee Sun Oh, Eun Jung Choi, Il Han Kim, Peter Atadja, Eric J. Bernhard
Radiotherapy and Oncology.2009; 92(1): 125. CrossRef
Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53
In Ah Kim, Jin Hee Shin, Il Han Kim, Jin Ho Kim, Jae Sung Kim, Hong Gyun Wu, Eui Kyu Chie, Sung Whan Ha, Charn Il Park, Gary D. Kao
Clinical Cancer Research.2006; 12(3): 940. CrossRef

12,457 View
73 Download
16 Crossref

Combined Chemoradiation of Advanced Pancreatic Cancer: Jee Young Jang, Ki Mun Kang, In Ah Kim, Ihi Bong Choi, Jai Hak Lee, Eung Kook Kim, Seung Nam Kim, Hee Sik Sun, Kyu Won Chung, Meung Kyu Choi, Joon Yeol Han, Han Lim Mun; J Korean Cancer Assoc. 1998;30(2):300-305.

Abstract PDF: PURPOSE
This study was designed to evaluate the survival rate and prognostic factor of patients with advanced pancreatic cancer who received chemoirradiation. MATERIAL AND METHODS: From March 1993 to November 1995, twenty patients with unresectable pancreatic cancer were treated at the Department of Therapeutic Radiology, St Mary's Hospital, Catholic University Medical College. There were 11 men and 9 women. Age at diagnosis ranged from 34 to 75 years. All patient were treated according to a protocol consisting of 40 Gy external radiation by split course concomitant with intravenous 5-fluorouracil (5-FU) 500 mg/m2 given in a bolus injection 4 hours before radiatian on each of the first 3 days of each treatment course. Among them, 5 patients received incomplete radiotherapy. The follow-up period ranged from 1.3 to 29 months.
RESULTS
In all the patients, median survival is 5.0 months and one and two-year overall survival rate was 34.3% and 25.8%, respectively. Median survival was 9.0 months and one-year survival rate was 33.3% in 15 patients with complete radiotherapy. The significant prognostic factors were stage, tumor location, and completion of chemoradio- therapy(p < 0.05).
CONCLUSION
A combination of radiotherapy and chemotherapy resulted in improved median survival. However, the significant prognostic factars affecting survival rate in this analysis need to be verified further through randomized trial.

2,283 View
13 Download

Electron Beam Therapy for the skin Cancer: Ki Mun Kang, Ihl Bohng Choi, Baik Kee Cho, Su Mi Chung, In Ah Kim, Kyung Sub Shinn; J Korean Cancer Assoc. 1994;26(4):626-631.

Abstract PDF: Purpose
This study was designed to determine the efficacy of electron beam therapy in skin cancer. Materials and Methods: From January l988 to March 1993, sixteen patients diagnosed as skin cancer of the face were treated by electron beam therapy at St. Marys HospitaL There were 8 men and 8 women. The median age was 62 years and the range 45 to 80 years. Twelve (75%) patietns had basal cell carcinoma, and 4(25%) patients had squamous cell carcinoma. According to American Joint Committee(AJC) classification, 12(75%) patients had Tl, and 4(25%) patients had T2. The median radiation dose was 5570 cGy in 5-7 weeks (range; 3980-7000 cGy). The median follow-up was 25.5 months with a range of 6 to 68 months. Results: The overall local control rate was 93.8% (15/16). By histologic classification, the local control rate was 91.7%(11/12) for basal cell carcinoma and 100%(4/4) for squamous cell carcinoma. The local control rate was 100%(12/12) for Tl, and 75%(3/4) for T2, Treatment induced complication was observed in 6.2%(l/16). Cosmetic outcomes were excellent to good in 93.8/(15 /16) of patients. Conclusion: For the skin cancer, especially in the face, electron beam therapy was a safe and effective modality and offered excellent cosmesis.

3,004 View
43 Download

Clinical Results of Allogeneic Bone Marrow Transplantation in Adults ( 2 ) : 1992 ~ 1995: Seok Goo Cho, Ik Joo Chung, Jung Hyun Choi, jing Hong You, Dogn Wook Kim, Chi Hwa Han, Woo Sung Min, Whan Sik Sin, Chong Won Park, Cjun Choo Kim, Dong Jip Kim, In Ah Kim, Su Mi Chung, Ihl Bhong Choi; J Korean Cancer Assoc. 1996;28(2):308-316.

Abstract PDF: Allogeneic bone marrow transplantation has been accepted as a powerful therapeutic modality to overcome for successfull clinical reuslts in malignant hematologic disease and severe aplastic anemia in spite of various barriers. We analysed 62 patients who had been admitted to Catholic BMT Center and have performed since malignant hematologic disesaes and severe aplastic anemia were determined to be the subject of National Public Health Care Program(between Oct. l992 and Mar. 1995). Number of patients with acute myelogenous leukemia(AML), acute lymphoblastic leukemia(ALL), chronic myelogenous leukemia(CML) and severe aplastic anemia(SAA) were 17, 4, 21, 20 respectively. We have used pretransplant conditionig regimens which were consisted of total body irradiation(TBI, fractionated 1320 cGy) and cyclophosphamide(CY, 120mg/kg) in leukemic disease(39/42) and anti-thymocyte globulin(ATG, 1.5 vial/10kg, Pasteur Merieux), CY(200mg/kg) and procar- baziine(6.25 mg/kg for 6 days, rutulard, Roche) in SAA(17/20). Cyclosporin A and short course methotrexate were used to prevent graft-versus-host disease(GVHD). Disease-free overall survival rate was 71% in aute leukemia, 67% in CML and 85% in SAA respectively. Maior complications were acute GVHD<35% grade I-IV among them, grade III-IV 14.5%),CMV antigenemia(l1.2%), herpes zoster(9.6%), veno-occlussive disease(8%), TTP-like syndrome(4.8%), chronic GVHD(3%) and interstitial pneumonia(1.6%). Major causes of death were leukemic relapse(9.7%), primary engraftment failure/rejection(6.5%), acute GVHD(3%) and TTP-like syndrome(3%). We suggest again that allogeneic BMT should be considered as the effective therapeutic modality to cure malignant hematologic diseases and aplastic anemia. For the purpose of obtaining better clinical outcome of allogeneic BMT, it should be early performed as soon as possible in clinial course.

2,257 View
14 Download

First
Prev
Page of 1
Next
Last

Search